var title_f26_42_27296="Keloids PI";
var content_f26_42_27296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keloids from acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A keloid is a growth that forms where the skin has healed from a cut or other injury. These keloids formed on skin that healed from acne.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27296=[""].join("\n");
var outline_f26_42_27296=null;
var title_f26_42_27297="Giardia cyst - trichrome stain";
var content_f26_42_27297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Giardia intestinalis cyst stained with trichrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites: Giardiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/HTML/ImageLibrary/Giardiasis_il.htm\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/HTML/ImageLibrary/Giardiasis_il.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27297=[""].join("\n");
var outline_f26_42_27297=null;
var title_f26_42_27298="Patient information: Staying healthy when you travel (The Basics)";
var content_f26_42_27298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/15/8434\">",
"         Patient information: Activity during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/9/19602\">",
"         Patient information: Jet lag (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/47/3826\">",
"         Patient information: Malaria (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/26/38305\">",
"         Patient information: Typhoid fever (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/22/33122\">",
"         Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Staying healthy when you travel (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/staying-healthy-when-you-travel-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H384528924\">",
"      <span class=\"h1\">",
"       Why should I think about my health before I travel?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are a few reasons:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Many travel destinations have germs that do not exist in the United States or other developed countries. When people from developed countries go to these places, they sometimes get infections.",
"       </li>",
"       <li>",
"        Travel itself can be a threat to your health. Flying, for example, can increase the risk of blood clots and other health problems.",
"       </li>",
"       <li>",
"        If you have an ongoing health problem, such as diabetes, it can be hard to find supplies or help if you get sick while you are away.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384528931\">",
"      <span class=\"h1\">",
"       How do I keep from getting an infection when I travel?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are planning to go to Asia, Africa, South America, or Eastern Europe, make an appointment at a travel clinic. The doctors and nurses there can help you prepare for your trip. Depending on your destination, you may need to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have one or more vaccines &mdash; weeks or months before you go. For example, if you are traveling to parts of Africa or South America, you might need to get a vaccine against yellow fever.",
"       </li>",
"       <li>",
"        Avoid ice, tap water, and certain foods or parts of foods that can carry germs. If you drink untreated water or certain foods, you might get an infection that causes diarrhea, vomiting, or other problems.",
"       </li>",
"       <li>",
"        Treat the water you drink, to make sure it has no germs that could cause infection. To get rid of germs, you can boil water for 3 minutes and then let it cool. Another way to get rid of germs is to take 2 quarts of water, add 2 drops of 5% bleach, and wait 30 minutes.",
"       </li>",
"       <li>",
"        Use bug spray that has DEET or a chemical called picaridin. You should also wear clothes that protect you from insect bites. Plus, you should check yourself for insects and remove them if you find any. Insects can infect you with germs they carry when they bite or sting you.",
"       </li>",
"       <li>",
"        Take medicines before and during your trip that can prevent infections such as malaria.",
"       </li>",
"       <li>",
"        Wear shoes that cover your feet completely if you are anywhere that might have traces of dog or human waste in the sand or soil. This can happen in places that do not have good plumbing or that do not treat toilet water before dumping it. If you walk barefoot in places like these, you can get infected with worms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384528938\">",
"      <span class=\"h1\">",
"       What if I have a health condition, but I want to travel?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have an ongoing health problem, such as diabetes or heart disease, ask your doctor or nurse how to plan for your trip.",
"     </p>",
"     <p>",
"      Many people with health concerns are able to travel without any problems. The key is to plan ahead, and to make sure you have all the medicines and supplies you might need. It&rsquo;s also important to bring a list of all the medicines you take, the doses, and why you take them.",
"     </p>",
"     <p>",
"      Here are some examples of special needs people might have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Some people with diabetes must carry pills, insulin, and syringes when they fly. They usually have a letter from their doctor explaining their needs.",
"       </li>",
"       <li>",
"        Some people with lung or heart disease need extra oxygen when they fly. That's because the air on a plane that is in-flight tends to have less oxygen than the air on the ground. People who need oxygen on the plane must arrange it with the airline before they fly.",
"       </li>",
"       <li>",
"        Some people with blood clotting problems or bad veins need to stand up and move around if they are on a long flight. Otherwise they can develop blood clots. They may also need to wear special stockings that improve blood flow in the legs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384528945\">",
"      <span class=\"h1\">",
"       What if I am pregnant and want to travel?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Travel is safe for most pregnant women. But women who have had problems during pregnancy, such as high blood pressure, should limit air travel. There are no known risks of air travel for an unborn baby.",
"     </p>",
"     <p>",
"      During long flights, pregnant women should stretch and flex their legs. They should also stand up and move around when it is safe to do so. This can prevent blood clots from forming in the legs.",
"     </p>",
"     <p>",
"      Some of the vaccines and medicines given to travelers are not safe for pregnant women. If you want to travel to a country where infection is a concern, ask your doctor or nurse if you can safely go there. Many doctors recommend that pregnant women not travel to places where there is malaria.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384528952\">",
"      <span class=\"h1\">",
"       What else should I think about when I travel?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are going to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A sunny or warm place, make sure to wear sunblock and clothes that block the sun. Getting too much sun can lead to sunburns and increase the risk of skin cancer.",
"       </li>",
"       <li>",
"        The mountains or a place at high altitude, ask your doctor how you can keep from getting sick",
"       </li>",
"       <li>",
"        A place with a lot of traffic, keep in mind that the rules of the road are often different in other countries. Be extra careful when driving or crossing the street.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384528959\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/15/8434?source=see_link\">",
"       Patient information: Activity during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/26/38305?source=see_link\">",
"       Patient information: Typhoid fever (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=see_link\">",
"       Patient information: Malaria (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=see_link\">",
"       Patient information: Jet lag (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"       Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/42/27298?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15363 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27298=[""].join("\n");
var outline_f26_42_27298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384528924\">",
"      Why should I think about my health before I travel?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384528931\">",
"      How do I keep from getting an infection when I travel?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384528938\">",
"      What if I have a health condition, but I want to travel?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384528945\">",
"      What if I am pregnant and want to travel?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384528952\">",
"      What else should I think about when I travel?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384528959\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/15/8434?source=related_link\">",
"      Patient information: Activity during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=related_link\">",
"      Patient information: Jet lag (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=related_link\">",
"      Patient information: Malaria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=related_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/26/38305?source=related_link\">",
"      Patient information: Typhoid fever (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_42_27299="Safe bedding for infants PI";
var content_f26_42_27299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Safe sleep position and bedding to reduce SIDS risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To reduce the risk that your baby will have sudden infant death syndrome (SIDS), do the following things every time your baby is going to sleep:",
"    <ul>",
"     <li>",
"      Put the baby to sleep on his or her back.",
"     </li>",
"     <li>",
"      Make sure the baby is on a firm surface. Babies should not sleep on sofas or beds designed for adults.",
"     </li>",
"     <li>",
"      Do NOT put any soft objects in the baby&rsquo;s crib, such as pillows or stuffed animals.",
"     </li>",
"     <li>",
"      If you use a blanket, put the baby&rsquo;s feet near the bottom of the&nbsp;crib (\"feet to foot\").&nbsp;Use a thin blanket and tuck it under the mattress. Make sure the blanket reaches only as far as the baby&rsquo;s chest.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27299=[""].join("\n");
var outline_f26_42_27299=null;
var title_f26_42_27300="2D TTE 4-chamber descending thoracic aorta";
var content_f26_42_27300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61910%7ECARD%2F60999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61910%7ECARD%2F60999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from a modified four-chamber view showing the descending thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 203px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thoracic or descending aorta (T Ao) can be imaged from the apical two and four chamber view. Posterior angulation (panel B) shows the T Ao in its short axis, located below the left atrium (LA). Anterior angulation in four chamber view (panel A) shows the origin of aortic root (Ao).",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mildly dilated thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis precordial view shows slight dilation of the thoracic aorta (Th Ao).",
"    <div class=\"footnotes\">",
"     CS: coronary sinus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27300=[""].join("\n");
var outline_f26_42_27300=null;
var title_f26_42_27301="Telavancin: Drug information";
var content_f26_42_27301=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Telavancin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/48/38659?source=see_link\">",
"    see \"Telavancin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11238847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8119746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vibativ&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8308550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Glycopeptide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9739342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Complicated skin and skin structure Infection:",
"     </b>",
"     I.V.: 10 mg/kg every 24 hours for 1-2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9739346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9739343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      <i>",
"       Note:",
"      </i>",
"     </b>",
"     <i>",
"      Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 7.5 mg/kg every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10 to &lt;30 mL/minute: 10 mg/kg every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute and hemodialysis patients: Dosage adjustment recommendations are not available; use caution or avoid.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9739344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment: no dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment: Has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9739353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vibativ&trade;: 250 mg, 750 mg [contains cyclodextrin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9739185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14291598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vibativ&trade;: Temporarily not commercially available; anticipated date of availability is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9739184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM183838.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM183838.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9739348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. over 60 minutes. Other medications should not be infused simultaneously through the same I.V. line. When the same intravenous line is used for sequential infusion of other medications, flush line with D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, or NS before and after infusing telavancin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red-man syndrome may occur if the infusion is too rapid. It is not an allergic reaction, but may be characterized by hypotension and/or a maculopapular rash appearing on the face, neck, trunk, and/or upper extremities. If this should occur, discontinuing or slowing the infusion rate may eliminate these reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9739218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amphotericin B lipid complex, ampicillin/sulbactam, azithromycin, calcium gluconate, caspofungin, cefepime, ceftazidime, ciprofloxacin, dexamethasone sodium phosphate, diltiazem, dobutamine, dopamine, doripenem, doxycycline, ertapenem, famotidine, fluconazole, gentamicin, hydrocortisone sodium succinate, labetalol, magnesium sulfate, mannitol, meropenem, metoclopramide, milrinone, norepinephrine, ondansetron, pantoprazole, phenylephrine, piperacillin/tazobactam, potassium chloride, potassium phosphate, ranitidine, sodium bicarbonate, sodium phosphate, tigecycline, tobramycin, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B liposome, digoxin, furosemide, levofloxacin, micafungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone, colistimethate, cyclosporine, heparin, imipenem/cilastatin, methylprednisolone sodium succinate, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8308551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of complicated skin and skin structure infections caused by susceptible gram-positive organisms including methicillin-susceptible or -resistant",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     , vancomycin-susceptible",
"     <i>",
"      Enterococcus faecalis",
"     </i>",
"     , and",
"     <i>",
"      Streptococcus pyogenes",
"     </i>",
"     ,",
"     <i>",
"      Streptococcus agalactiae",
"     </i>",
"     , or",
"     <i>",
"      Streptococcus anginosus",
"     </i>",
"     group",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8308548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Telavancin may be confused with telithromycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vibativ&trade; may be confused with Viactiv&reg;, Vibramycin&reg;, vigabatrin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9739208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (13%), psychiatric disorder (12%), headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Metallic/soapy taste (33%), nausea (27%), vomiting (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Foamy urine (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3% to 6%), rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (7%), appetite decreased (3%), abdominal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Infusion site pain (4%), infusion site erythema (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (5%), rigors (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Serum creatinine increased (8%), microalbuminuria (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening):",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea, hearing loss (transient), QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prolongation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9739191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9739192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Altered cardiac conduction: May prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; avoid use in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, uncompensated heart failure, severe left ventricular hypertrophy, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants). Clinical studies indicate mean maximal QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation of 12-15 msec at the end of 10 mg/kg infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Nephrotoxicity: May cause nephrotoxicity; usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. Monitor renal function prior to, during, and following therapy. Contains solubilizer cyclodextrin (hydroxypropyl-beta-cyclodextrin) which may accumulate in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment or those receiving other nephrotoxic drugs; dosage modification required and efficacy may be reduced in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Lower doses are often required secondary to age-related decreases in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Based on animal data, adverse developmental outcomes have been observed. Prior to use, women of childbearing potential should have a serum pregnancy test. Use of telavancin is not recommended during pregnancy unless the potential benefit outweighs the risk to the fetus.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Coagulation tests: May interfere with tests used to monitor coagulation (eg, prothrombin time, INR, activated partial thromboplastin time, activated clotting time, coagulation based factor Xa tests) when samples drawn &le;18 hours after drug administration. Blood samples should be collected as close to the next dose of telavancin as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion reactions: Rapid I.V. administration may result in flushing, rash, urticaria, and/or pruritus; slowing or stopping the infusion may alleviate these symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9613187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9739187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9739188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Based on animal data, adverse developmental outcomes have been observed. Prior to use, women of childbearing potential should have a serum pregnancy test. Use of telavancin is not recommended during pregnancy unless the potential benefit to the mother outweighs the possible risk to the fetus.",
"     </b>",
"     Telavancin crosses the placenta. In women of childbearing potential, effective contraception should be used during therapy. Healthcare providers are encouraged to enroll women exposed to telavancin during pregnancy in the Vibativ Pregnancy Registry (888-658-4228).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9739190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14456864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if telavancin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering telavancin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Vibativ Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $75.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (1): $224.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9739351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, pregnancy test",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9739219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exerts concentration-dependent bactericidal activity; inhibits bacterial cell wall synthesis by blocking polymerization and cross-linking of peptidoglycan by binding to D-Ala-D-Ala portion of cell wall. Unlike vancomycin, additional mechanism involves disruption of membrane potential and changes cell permeability due to presence of lipophilic side chain moiety.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9739293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~90%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 6.6-9.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~76%); feces (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus Aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27301/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stryjewski ME, Chu VH, O&rsquo;Riordan WD, et al, &ldquo;Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Bacteria: Fast 2 Study,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2006, 50(3):862-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27301/abstract-text/16495243/pubmed\" id=\"16495243\" target=\"_blank\">",
"        16495243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stryjewski ME, Graham DR, Wilson SE, et al, &ldquo;Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Organisms,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(11):1683-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27301/abstract-text/18444791/pubmed\" id=\"18444791\" target=\"_blank\">",
"        18444791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stryjewski ME, O&rsquo;Riordan WD, Lau WK, et al, &ldquo;Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 40(11):1601-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27301/abstract-text/15889357/pubmed\" id=\"15889357\" target=\"_blank\">",
"        15889357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson SE, O&rsquo;Riordan W, Hopkins A, et al, &ldquo;Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Associated With Surgical Procedures,&rdquo;",
"      <i>",
"       Am J Surg",
"      </i>",
"      , 2009, 197(6):791-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27301/abstract-text/19095213/pubmed\" id=\"19095213\" target=\"_blank\">",
"        19095213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9535 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27301=[""].join("\n");
var outline_f26_42_27301=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238847\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119746\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8308550\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739342\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739346\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739343\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739344\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739353\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739185\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14291598\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739184\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739348\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739218\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8308551\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8308548\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739208\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739191\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739192\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300108\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613187\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739187\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739188\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739190\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456864\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322696\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739351\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739219\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9739293\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9535\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9535|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/48/38659?source=related_link\">",
"      Telavancin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_42_27302="Thiotepa: Pediatric drug information";
var content_f26_42_27302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thiotepa: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"    see \"Thiotepa: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/12/35012?source=see_link\">",
"    see \"Thiotepa: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"      see \"Thiotepa: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HSCT for CNS malignancy (combination chemotherapy): 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose daily for 3 days (Dunkel, 2010; Finlay, 2008; Gilheeney, 2010; Grodman, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HSCT for neuroblastoma/solid tumors (combination chemotherapy): Children and Adolescents: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose daily for 3 days (Kletzel, 1998; Kushner, 2001; Kushner, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Ovarian, breast cancer: 0.3-0.4 mg/kg/dose every 1-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intracavitary: Effusions: 0.6-0.8 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intrathecal: Leptomeningeal metastases: 10 mg twice a week for 4 weeks, then weekly for 4 weeks, then monthly for 4 doses (NCCN CNS cancer guidelines v.1.2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intravesical: Bladder cancer: 60 mg in 30-60 mL NS retained for 2 hours once weekly for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Use with extreme caution; reduced dose may be warranted. Use may be contraindicated with existing renal impairment and should be limited to cases where benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use with extreme caution; reduced dose may be warranted. Use may be contraindicated with existing hepatic impairment and should be limited to cases where benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hematologic toxicity:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC &le;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets &le;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use may be contraindicated with pre-existing marrow damage and should be limited to cases where benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bladder instillation: Prepare with 60 mg diluted in 30-60 mL NS and instill by catheter and retain for 2 hours; patients should reposition every 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrapleural or pericardial: Dose is further diluted to a volume of 10-20 mL in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal: Reconstitute each 15 mg vial with 1.5 mL preservative-free SWI then further dilute to a final concentration of 1-5 mg/mL with preservative-free NS. Intrathecal dilutions are preservative-free and should be used as soon as possible after preparation. After preparation, store intrathecal medications (until use) in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Use appropriate precautions for handling and disposal. Reconstitute each 15 mg vial with 1.5 mL SWI to a concentration of 10 mg/mL. Solutions for I.V. use should be further diluted in NS prior to infusion. Filter through a 0.22 micron filter (polysulfone membrane [eg, Sterile Aerodisc&reg;] or triton-free cellulose mixed ester [eg, Millex&reg;-GS]) prior to administration; do not use solutions which precipitate or remain opaque after filtering. Low doses (adult) may be administered as a rapid injection over 5 minutes. High doses (pediatric) have longer infusion times (eg, over 2- to 4-hour infusion); refer to specific protocols.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F227210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amikacin, aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin HCl, dexamethasone sodium phosphate, diphenhydramine, dobutamine, dopamine, doxorubicin HCl, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, idarubicin, ifosfamide, imipenem/cilastatin, leucovorin calcium, lorazepam, magnesium sulfate, mannitol, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, mitomycin, mitoxantrone, morphine, nalbuphine, ofloxacin, ondansetron, paclitaxel, piperacillin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, streptozocin, teniposide, ticarcillin/clavulanate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible",
"     </b>",
"     : Cisplatin, filgrastim, minocycline, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials under refrigeration (2&deg;C to 8&deg;C). Protect from light. Reconstituted solutions (10 mg/mL) are stable for up to 28 days under refrigeration (4&deg;C to 8&deg;C) or 7 days at room temperature (25&deg;C), although the manufacturer recommends use within 8 hours when reconstituted solutions are stored under refrigeration. Solutions further diluted (for I.V. use) in NS to 1 mg/mL in NS are stable for 24 hours and  to 3 mg/mL are stable for 48 hours at room temperature, although the manufacturer recommends immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial tumors of the bladder; palliative treatment of adenocarcinoma of breast or ovary; control of pleural, pericardial, or peritoneal effusions caused by metastatic tumors (FDA approved in adults); has also been used for intrathecal treatment of leptomeningeal metastases (in adults) and as part of a conditioning regimen prior to autologous or allogeneic hematopoietic stem cell transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Thiotepa may be confused with thioguanine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       <i>",
"        Intrathecal medication safety:",
"       </i>",
"       The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Intrathecal medication should not be prepared during the preparation of any other agents",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; After preparation, keep in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Delivery to the patient should only be with other medications intended for administration into the central nervous system",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F227209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, contact dermatitis, depigmentation (with topical treatment), dermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, spermatogenesis inhibition",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, epistaxis, laryngeal edema, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylactic shock, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening:  Acute myeloid leukemia (AML), chemical cystitis (bladder instillation), hemorrhagic cystitis (bladder instillation), myelodysplastic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thiotepa or any component;",
"     <b>",
"      Note:",
"     </b>",
"     May be contraindicated in certain circumstances of hepatic, renal, and/or bone marrow failure; evaluate on an individual basis as lower dose treatment may still be appropriate if the potential benefit outweighs the risks.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage in patients with hepatic, renal, or bone marrow dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Myelosuppression is common; monitor for infection or bleeding. Death due to sepsis and hemorrhage as a result of thiotepa administration has been reported. Thiotepa is potentially mutagenic, carcinogenic, teratogenic, and may cause fertility impairment. May be contraindicated with hepatic, renal, and/or bone marrow impairment/damage; use should be limited to cases in which benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Strong) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3881813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and fetal loss. There  are no adequate and well-controlled studies in pregnant women. May cause harm if administered during pregnancy. Effective contraception is recommended for men and women of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, uric acid, urinalysis, renal and hepatic function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Polyfunctional alkylating agent that reacts with DNA phosphate groups to produce cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable absorption through serous membranes and from I.M. injection sites; bladder mucosa: 10% to 100% and is increased with mucosal inflammation or tumor infiltration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.7-1.6 L/kg; distributes into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 8% to 13%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via oxidative desulfuration (cytochrome P450 microsomal enzyme system) primarily to TEPA (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thiotepa: 109 minutes (51.6-212 minutes) with dose-dependent clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEPA: 10-21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Very little thiotepa or active metabolite are excreted unchanged in urine (1.5% of thiotepa dose)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/12/35012?source=see_link\">",
"      see \"Thiotepa: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, sore throat, urine color change, bleeding, or bruising occurs. Patients of childbearing potential should avoid becoming pregnant while on thiotepa therapy. Effective contraception should be used if either the patient or partner is of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Severe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 7-10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 14-20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 28",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dunkel IJ, Gardner SL, Garvin JH Jr, et al, \"High-Dose Carboplatin, Thiotepa, and Etoposide With Autologous Stem Cell Rescue for Patients With Previously Irradiated Recurrent Medulloblastoma,\"",
"      <i>",
"       Neuro Oncol",
"      </i>",
"      , 2010, 12(3):297-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/20167818/pubmed\" id=\"20167818\" target=\"_blank\">",
"        20167818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finlay JL, Dhall G, Boyett JM, et al, \"Myeloablative Chemotherapy With Autologous Bone Marrow Rescue in Children and Adolescents With Recurrent Malignant Astrocytoma: Outcome Compared With Conventional Chemotherapy: A Report From the Children's Oncology Group,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 51(6):806-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/18802947/pubmed\" id=\"18802947\" target=\"_blank\">",
"        18802947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilheeney SW, Khakoo Y, Souweidane M, et al, \"Thiotepa/Topotecan/Carboplatin With Autologous Stem Cell Rescue in Recurrent/Refractory/Poor Prognosis Pediatric Malignancies of the Central Nervous System,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2010, 54(4):591-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/19998470/pubmed\" id=\"19998470\" target=\"_blank\">",
"        19998470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grodman H, Wolfe L, and Kretschmar C, \"Outcome of Patients With Recurrent Medulloblastoma or Central Nervous System Germinoma Treated With Low Dose Continuous Intravenous Etoposide Along With Dose-Intensive Chemotherapy Followed by Autologous Hematopoietic Stem Cell Rescue,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(1):33-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/19326417/pubmed\" id=\"19326417\" target=\"_blank\">",
"        19326417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman SA, Finkelstein DM, Ruckdeschel JC, et al, \"Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(3):561-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/8445432/pubmed\" id=\"8445432\" target=\"_blank\">",
"        8445432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, \"American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heideman R, Cole D, Balis F, et al, \"Phase I and Pharmacokinetic Evaluation of Thiotepa in the Cerebrospinal Fluid and Plasma of Pediatric Patients: Evidence for Dose-Dependent Plasma Clearance of Thiotepa,\"",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1989, 49(3):736-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/2491958/pubmed\" id=\"2491958\" target=\"_blank\">",
"        2491958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kletzel M, Abella EM, Sandler ES, et al, \"Thiotepa and Cyclophosphamide With Stem Cell Rescue for Consolidation Therapy for Children With High-Risk Neuroblastoma: A Phase I/II Study of the Pediatric Blood and Marrow Transplant Consortium,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 1998, 20(1):49-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/9482413/pubmed\" id=\"9482413\" target=\"_blank\">",
"        9482413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner BH, Cheung NK, Kramer K, et al, \"Topotecan Combined With Myeloablative Doses of Thiotepa and Carboplatin for Neuroblastoma, Brain Tumors, and Other Poor-Risk Solid Tumors in Children and Young Adults,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2001, 28(6):551-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/11607767/pubmed\" id=\"11607767\" target=\"_blank\">",
"        11607767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner BH, Kramer K, Modak S, et al, \"Topotecan, Thiotepa, and Carboplatin for Neuroblastoma: Failure to Prevent Relapse in the Central Nervous System,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2006, 37(3):271-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/16400336/pubmed\" id=\"16400336\" target=\"_blank\">",
"        16400336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), \"Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,\" Version 2.2009. Available at: file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soussain C, Hoang-Xuan K, Taillandier L, et al, \"Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle Osseuse-Th&eacute;rapie Cellulaire,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15):2512-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/42/27302/abstract-text/18413641/pubmed\" id=\"18413641\" target=\"_blank\">",
"        18413641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12838 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27302=[""].join("\n");
var outline_f26_42_27302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050283\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050275\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227149\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227134\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050287\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227210\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050278\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050286\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402289\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227209\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050290\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050274\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050273\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227199\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227143\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227145\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3881813\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050282\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050272\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050289\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050280\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050291\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=related_link\">",
"      Thiotepa: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/12/35012?source=related_link\">",
"      Thiotepa: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_42_27303="Hematologic problems in children and adolescents with systemic lupus erythematosus";
var content_f26_42_27303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematologic problems in children and adolescents with systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27303/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27303/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27303/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27303/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27303/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27303/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27303/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/42/27303/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic abnormalities are common among children and adolescents who have systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Leukopenia occurs in nearly two-thirds of children at some point during the course of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. Anemia is present in 50 to 75 percent of affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/3,4,7\">",
"     3,4,7",
"    </a>",
"    ]. The reported prevalence of thrombocytopenia varies from 10 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/1-5,8,9\">",
"     1-5,8,9",
"    </a>",
"    ], and for antiphospholipid antibodies from 24 to 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and management of hematologic abnormalities in children and adolescents with SLE are discussed here. An overview of SLE in children is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LEUKOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia, defined as a total white blood cell (WBC) count less than",
"    <span class=\"nowrap\">",
"     4000/microL",
"    </span>",
"    in the American College of Rheumatology (ACR) guidelines, occurs in two-thirds of children with active SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/2\">",
"     2",
"    </a>",
"    ]. Typically the WBC count in these children ranges from 2000 to",
"    <span class=\"nowrap\">",
"     4000/microL.",
"    </span>",
"    The decrease in WBC count is primarily due to a fall in absolute lymphocyte count accompanied by an increase in granulocyte percentage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Neutropenia is uncommon in SLE; when it occurs, it is usually associated with severe infection or drug effect (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=see_link\">",
"     \"Infectious causes of neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia in children with SLE usually resolves as disease activity is brought under control. Neutropenia is the exception. When granulocytopenia is secondary to infection,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) may be used to increase the neutrophil count [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/15\">",
"     15",
"    </a>",
"    ]. Neutropenia secondary to drug toxicity typically responds to lowering the drug dose or temporarily discontinuing the relevant drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link&amp;anchor=H11#H11\">",
"     \"Systemic lupus erythematosus in children\", section on 'Therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia, defined as a hemoglobin concentration more than two standard deviations below the mean for age and sex (",
"    <a class=\"graphic graphic_table graphicRef57465 \" href=\"UTD.htm?5/34/5679\">",
"     table 1",
"    </a>",
"    ), is a common manifestation of SLE, with the majority of patients developing this problem at some point during the course of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/3,4,16\">",
"     3,4,16",
"    </a>",
"    ]. The most common types of anemia in children with SLE are anemia of chronic disease, iron deficiency anemia, and autoimmune hemolytic anemia. These may be seen separately or in combination. Although other causes of anemia in SLE are rare, severe direct antiglobulin test (Coombs) positive hemolytic anemia, autoimmune hemolysis, aplastic anemia, and pure red cell aplasia have all been described in children with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/17\">",
"     17",
"    </a>",
"    ]. An ongoing source of bleeding (eg, lungs, gastrointestinal tract) should be sought if the direct antiglobulin test is negative in the presence of an elevated reticulocyte count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in children\", section on 'Acute pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anemia of chronic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia of chronic disease is the most common type of anemia in SLE. The pathophysiology is not well understood. The peripheral blood smear typically reveals a normochromic and normocytic picture but may be hypochromic and microcytic. Serum iron concentrations are usually reduced, but bone marrow examination reveals normal to increased iron stores. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to leukopenia, the anemia of chronic disease in children with SLE typically resolves as the disease is brought under control. Iron therapy is not helpful if there are adequate iron stores. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link&amp;anchor=H11#H11\">",
"     \"Systemic lupus erythematosus in children\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency anemia is particularly common in female adolescents with SLE for three reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Body mass usually increases, whereas iron stores do not",
"     </li>",
"     <li>",
"      Dietary choices tend to decrease iron intake (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16778?source=see_link\">",
"       \"Adolescent eating habits\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heavy menstruation during the first years after menarche increases iron losses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, many patients have mild gastrointestinal blood loss secondary to NSAID and glucocorticoid therapy. Often there is a combination of iron deficiency anemia and anemia of chronic disease. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Anemia of chronic disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment for iron deficiency anemia in children and adolescents with SLE is the same as it is for those without SLE: 3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of elemental iron orally. The efficacy of this therapy is demonstrated by an increase in the reticulocyte count within three days of initiating therapy. Only in rare cases is parenteral iron required [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link\">",
"     \"Iron deficiency in infants and young children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hemolytic anemia (AIHA) is a relatively common cause of anemia in children and adolescents with SLE. Although studies documenting the prevalence of AIHA in children with SLE are lacking, AIHA appears to be more common than the 7 to 15 percent described in adults with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with idiopathic AIHA go on to develop SLE after months or even years. However, there is also a group of patients with idiopathic AIHA who are antinuclear antibody (ANA) positive who do not progress to full-blown SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/20\">",
"     20",
"    </a>",
"    ]. AIHA in children with SLE is typically of mild to moderate severity, but it may be severe.",
"   </p>",
"   <p>",
"    AIHA in SLE is usually the warm-reactive type in which IgG antibodies react with red cell surface antigens at 37&ordm;C. These cells are then removed from the circulation, primarily by the spleen. The cold type of AIHA is caused by the binding of IgM complement-fixing antibody to red cell antigens at 4&ordm;C. These cells are also removed from the circulation, primarily by the liver (",
"    <a class=\"graphic graphic_figure graphicRef64888 \" href=\"UTD.htm?37/9/38046\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H6#H6\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Pathophysiology of red cell destruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic corticosteroids are the first-line therapy for AIHA in children with SLE. Mild to moderate cases are treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . Cases of severe rapidly progressive anemia may respond to intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    administered as a bolus of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three days (maximum daily dose 1g), followed by tapering daily oral doses of prednisone as the response to therapy allows. Children with hemolytic anemia may benefit from supplemental vitamins, especially folate, in view of their increased metabolic synthesis of red cells.",
"   </p>",
"   <p>",
"    Second-line therapies reserved for those patients who do not respond to corticosteroids include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5301?source=see_link\">",
"     danazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/21\">",
"     21",
"    </a>",
"    ], intravenous gamma globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/22\">",
"     22",
"    </a>",
"    ], and plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     Rituximab",
"    </a>",
"    has proven useful in adults with SLE who failed other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/24\">",
"     24",
"    </a>",
"    ], and in children in my experience.",
"   </p>",
"   <p>",
"    Splenectomy should be used only in life-threatening circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H32#H32\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant thrombocytopenia, defined as a platelet count of less than",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    in ACR guidelines, occurs in approximately 50 percent of children with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/9\">",
"     9",
"    </a>",
"    ]. As a general rule, the degree of thrombocytopenia is mild, and hemorrhage is rare. However, the correlation between the number of platelets and the likelihood of bleeding is poor. Some patients hemorrhage with platelet counts",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL,",
"    </span>",
"    whereas others have no bleeding with platelet counts",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL.",
"    </span>",
"    In some cases these differences are related to the severity and activity of other manifestations of SLE or to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=see_link\">",
"     \"Clinical manifestations and evaluation of thrombocytopenia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common clinical manifestations of thrombocytopenia are petechiae, purpura, and ecchymoses, particularly on the lower arms and legs. Bleeding of the gums, epistaxis, unusually heavy menstrual flow, and even intracranial hemorrhage can also occur.",
"   </p>",
"   <p>",
"    Idiopathic thrombocytopenic purpura (ITP), usually a disease sui generis, may be the first manifestation of SLE, antedating this diagnosis by many years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. This evolution occurs in up to 15 percent of patients with ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/30\">",
"     30",
"    </a>",
"    ]; a greater percentage of patients have or develop a positive ANA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/31\">",
"     31",
"    </a>",
"    ]. It is important that hematologists caring for children with a positive ANA and ITP remember to periodically look for evidence of SLE manifestations in other organ systems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombotic thrombocytopenic purpura (TTP) is rare in children. The pentad of fever, thrombocytopenia, neurologic and renal abnormalities, and a microangiopathic hemolytic anemia is caused by the presence of an antibody to a von Willebrand factor-cleaving protease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/32\">",
"     32",
"    </a>",
"    ]. As illustrated by case reports of TTP occurring in association with SLE in children, this is an acute and life-threatening complication [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombocytopenia in neonates may occur secondary to transplacental passage of maternal antibodies, as in neonatal lupus, a detailed discussion of which is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids, usually",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , are the first-line therapy for thrombocytopenia in SLE. Refractory cases, and those in which there is active hemorrhage, are treated with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    administered as a bolus of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three days (maximum daily dose 1 g). Intravenous gamma globulin also may be used, but is usually reserved for severe, life-threatening bleeding.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5301?source=see_link\">",
"     danazol",
"    </a>",
"    are used in patients who fail to respond to corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    for both adults and children with this complication has been noted to be efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/36\">",
"     36",
"    </a>",
"    ]. As with AIHA, splenectomy should be avoided unless absolutely necessary.",
"   </p>",
"   <p>",
"    TTP is an extremely serious cause of thrombocytopenia, and rapidly causes death in a majority of untreated patients. The prompt institution of therapy with plasmapheresis greatly improves prognosis in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTIPHOSPHOLIPID ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with childhood SLE may have antiphospholipid antibodies (aPL). These antibodies are found in increased frequency in children with SLE and are associated with thrombocytopenia, prolonged clotting times (eg, activated partial thromboplastin time), unexplained thrombosis, and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/38\">",
"     38",
"    </a>",
"    ]. However, they are also found in many children with SLE without these complications. The prevalence of APL in children and adolescents with SLE has been evaluated in several small cross-sectional cohort studies and ranges from 24 to 62 percent for lupus anticoagulant to 27 to 66 percent for anticardiolipin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Children and adolescents with APL should be presumed to have the same increased risk of developing a clotting disorder as adults with APL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of children and adolescents with SLE and APL remains controversial. Often these patients are treated with low-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    if they have not had thrombosis. If thrombosis has occurred,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    should be added. The dose of warfarin must be titrated for the individual patient, with a goal of maintaining an INR of 2 to 3. The usual dose is between 2 and 10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    titrating to an antifactor-Xa level of 0.5 to 1",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    is an alternative if warfarin is not tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MACROPHAGE ACTIVATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrophage activation syndrome (MAS) is a rare but serious and potentially life-threatening complication of all rheumatic diseases in childhood, including SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/39\">",
"     39",
"    </a>",
"    ]. Although data are limited, the reported incidence ranges from 1 to 4.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/40\">",
"     40",
"    </a>",
"    ]. MAS is caused by an activation of T lymphocytes and macrophages resulting in a massive release of proinflammatory cytokines (eg, interleukin 1beta, and 6, interferon gamma, and tumor necrosis factor). Clinical manifestations include persistent high fever, pancytopenia, hepatosplenomegaly, hepatic dysfunction, coagulation abnormalities, encephalopathy, and markedly elevated levels of ferritin. The pathognomonic bone marrow finding is the active phagocytosis of hematopoietic cells by benign looking macrophages.",
"   </p>",
"   <p>",
"    In one case series of 38 patients (20 with definite MAS and 18 with probable MAS), most episodes of MAS occurred within one to six months after the initial diagnosis with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27303/abstract/39\">",
"     39",
"    </a>",
"    ]. There were apparent triggers for MAS in about three-quarters of the patients, which included disease flare, infection, or change in medication. There were four deaths attributed to MAS.",
"   </p>",
"   <p>",
"    MAS including its treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukopenia is a common manifestation of SLE, and is typically manifested as lymphopenia, which resolves as disease activity is brought under control. Neutropenia is uncommon in SLE; when it occurs, it is usually associated with severe infection or drug effect. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Leukopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anemia is commonly seen in patients with SLE and is usually related to the anemia of chronic disease, iron deficiency,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      autoimmune hemolytic anemia (AIHA). These anemias are usually mild to moderate and can usually be controlled with conservative therapy and resolve as disease activity is brought under control. An ongoing source of bleeding (eg, lungs, gastrointestinal tract) should be sought if the direct antiglobulin test (Coombs) is negative in the presence of an elevated reticulocyte count. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thrombocytopenia is relatively common, and it, too, is usually mild to moderate in its severity. SLE may be preceded by either AIHA or idiopathic thrombocytopenia in the presence of positive ANA for prolonged periods of time. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematologic complications of SLE in children include antiphospholipid and macrophage activation syndromes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antiphospholipid antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Macrophage activation syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corticosteroids are successfully used to treat most of the hematologic manifestations of SLE. However, in patients unresponsive to steroids and those with unusual conditions (eg, the macrophage activation syndrome and thrombotic thrombocytopenic purpura), other approaches are necessary.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       Rituximab",
"      </a>",
"      is increasingly be used in adults and children with hematologic complications of SLE unresponsive to routine therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/1\">",
"      Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/2\">",
"      JACOBS JC. SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDHOOD. REPORT OF THIRTY-FIVE CASES, WITH DISCUSSION OF SEVEN APPARENTLY INDUCED BY ANTICONVULSANT MEDICATION, AND OF PROGNOSIS AND TREATMENT. Pediatrics 1963; 32:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/3\">",
"      Caeiro F, Michielson FM, Bernstein R, et al. Systemic lupus erythematosus in childhood. Ann Rheum Dis 1981; 40:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/4\">",
"      COOK CD, WEDGWOOD RJ, CRAIG JM, et al. Systemic lupus erythematosus. Description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatrics 1960; 26:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/5\">",
"      Fish AJ, Blau EB, Westberg NG, et al. Systemic lupus erythematosus within the first two decades of life. Am J Med 1977; 62:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/6\">",
"      King KK, Kornreich HK, Bernstein BH, et al. The clinical spectrum of systemic lupus erythematosus in childhood. Arthritis Rheum 1977; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/7\">",
"      Iqbal S, Sher MR, Good RA, Cawkwell GD. Diversity in presenting manifestations of systemic lupus erythematosus in children. J Pediatr 1999; 135:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/8\">",
"      Karpatkin S, Strick N, Karpatkin MB, Siskind GW. Cumulative experience in the detection of antiplatelet antibody in 234 patients with idiopathic thrombocytopenic purpura, systemic lupus erythematosus and other clinical disorders. Am J Med 1972; 52:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/9\">",
"      Schmugge M, Revel-Vilk S, Hiraki L, et al. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr 2003; 143:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/10\">",
"      Berube C, Mitchell L, Silverman E, et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Pediatr Res 1998; 44:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/11\">",
"      Seaman DE, Londino AV Jr, Kwoh CK, et al. Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Pediatrics 1995; 96:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/12\">",
"      Grigor R, Edmonds J, Lewkonia R, et al. Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis 1978; 37:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/13\">",
"      Rivero SJ, D&iacute;az-Jouanen E, Alarc&oacute;n-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978; 21:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/14\">",
"      HARVEY AM, SHULMAN LE, TUMULTY PA, et al. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 1954; 33:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/15\">",
"      Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997; 24:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/16\">",
"      Voulgarelis M, Kokori SI, Ioannidis JP, et al. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis 2000; 59:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/17\">",
"      Wolach B, Choc L, Pomeranz A, et al. Aplastic anemia in neonatal lupus erythematosus. Am J Dis Child 1993; 147:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/18\">",
"      Macdougall IC. Intravenous administration of iron in epoetin-treated haemodialysis patients--which drugs, which regimen? Nephrol Dial Transplant 2000; 15:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/19\">",
"      Alger M, Alarcon-Segovia D, Rivero SJ. Hemolytic anemia and thrombocytopenic purpura: two related subsets of systemic lupus erythematosus. J Rheumatol 1977; 4:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/20\">",
"      Miescher PA, Tucci A, Beris P, Favre H. Autoimmune hemolytic anemia and/or thrombocytopenia associated with lupus parameters. Semin Hematol 1992; 29:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/21\">",
"      Ahn YS, Harrington WJ, Mylvaganam R, et al. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 1985; 102:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/22\">",
"      Majer RV, Hyde RD. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin Lab Haematol 1988; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/23\">",
"      von Keyserlingk H, Meyer-Sabellek W, Arntz R, Haller H. Plasma exchange treatment in autoimmune hemolytic anemia of the warm antibody type with renal failure. Vox Sang 1987; 52:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/24\">",
"      Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006; 15:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/25\">",
"      Rivero SJ, Alger M, Alarc&oacute;n-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. Arch Intern Med 1979; 139:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/26\">",
"      Hepburn MJ, English JC 3rd, Keeling JH 3rd. Autoimmune idiopathic thrombocytopenic purpura with the subsequent occurrence of systemic lupus erythematosus. Cutis 1997; 60:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/27\">",
"      Lepore L, Salvatore CM, Pahor T, et al. Slow evolution to systemic lupus erythematosus of isolated autoimmune thrombocytopenia. Clin Exp Rheumatol 2000; 18:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/28\">",
"      Mitra S, Marwaha N, Marwaha RK, et al. Immune thrombocytopenic purpura with multiple auto-antibodies: evolution into systemic lupus erythematosus. Indian Pediatr 2000; 37:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/29\">",
"      Mestanza-Peralta M, Ariza-Ariza R, Cardiel MH, Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997; 24:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/30\">",
"      Karpatkin S. Autoimmune thrombocytopenic purpura. Blood 1980; 56:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/31\">",
"      Firkin BG, Buchanan RR, Pfueller S, Ryan P. Lupoid thrombocytopenia. Aust N Z J Med 1987; 17:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/32\">",
"      Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/33\">",
"      Bray VJ, West SG, Kristo DA. Simultaneous presentation of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J 1994; 87:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/34\">",
"      Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum 1999; 42:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/35\">",
"      Sakarcan A, Stallworth J. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case and review. Pediatr Nephrol 2001; 16:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/36\">",
"      Niewold TB, Alpert D, Scanzello CR, Paget SA. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol 2006; 33:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/37\">",
"      Stricker RB, Davis JA, Gershow J, et al. Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era. J Rheumatol 1992; 19:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/38\">",
"      McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/39\">",
"      Parodi A, Dav&igrave; S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009; 60:3388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27303/abstract/40\">",
"      Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 2008; 47:1686.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6410 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27303=[""].join("\n");
var outline_f26_42_27303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LEUKOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anemia of chronic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTIPHOSPHOLIPID ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MACROPHAGE ACTIVATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6410|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/9/38046\" title=\"figure 1\">",
"      Immune clearance of red cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6410|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/34/5679\" title=\"table 1\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16778?source=related_link\">",
"      Adolescent eating habits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=related_link\">",
"      Clinical manifestations and evaluation of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=related_link\">",
"      Infectious causes of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=related_link\">",
"      Iron deficiency in infants and young children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_42_27304="Giant proerythroblast in PRCA";
var content_f26_42_27304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant proerythroblast in pure red cell aplasia due to parvovirus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow from a patient with pure red cell aplasia due to parvovirus B19 infection, showing a characteristic giant proerythroblast. Compare the size of this cell with that of the surrounding cells of the neutrophilic series and the mature red blood cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal bone marrow biopsy at low power",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27304=[""].join("\n");
var outline_f26_42_27304=null;
var title_f26_42_27305="Electrophysiologic cardiac mapping: Use in specific arrhythmias";
var content_f26_42_27305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrophysiologic cardiac mapping: Use in specific arrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27305/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27305/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27305/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/42/27305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac mapping during electrophysiologic testing is the process of identifying the temporal and spatial distributions of electrical potentials generated by the myocardium during normal or abnormal rhythms. This process describes the spread of activation from its initiation to its completion within a region of interest, and in its usual application, is focused towards the identification of the site of origin or a critical site of conduction for an arrhythmia. Although traditionally aimed at detecting myocardial activation, cardiac mapping applications have expanded to include the measurement and display of other factors such as repolarization and scarring.",
"   </p>",
"   <p>",
"    Highly effective transcatheter techniques for ablation of most types of supraventricular tachycardia as well as different kinds of ventricular tachycardia (VT) have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. These mapping techniques, including electroanatomic mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and noncontact endocardial mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/8\">",
"     8",
"    </a>",
"    ], have all but replaced intraoperative mapping, which is now rarely performed.",
"   </p>",
"   <p>",
"    The application of these various techniques for mapping of specific arrhythmias will be reviewed here. The techniques for cardiac mapping are described elsewhere as are the details involved in the diagnosis, mapping, and treatment of specific arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAPPING OF SPECIFIC TACHYARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preexcitation syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several parameters can be utilized to identify an accessory pathway location during catheter-based mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To determine the atrial insertion site, the earliest site of retrograde atrial activation during orthodromic atrioventricular (AV) reciprocating tachycardia (AVRT) or ventricular pacing must be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The assumption is that the local retrograde ventriculoatrial (VA) interval on the recording electrode will be shortest at the atrial insertion site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared to pacing at sites more remote from the accessory pathway, atrial pacing near the atrial insertion of the accessory pathway will create a greater degree of preexcitation with a shorter delay between the stimulus and the onset of the delta wave [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/12\">",
"     12",
"    </a>",
"    ]. By pacing at various right and left atrial sites and measuring the degree of preexcitation and the stimulus-delta wave onset interval (so-called differential pacing), the site of the accessory pathway can be approximated.",
"   </p>",
"   <p>",
"    More precise localization of the ventricular insertion site is obtained by mapping along the AV groove in sinus rhythm to determine the site of earliest ventricular activation during preexcited beats. Local ventricular activation at the ventricular insertion site frequently precedes the onset of the delta wave on the surface ECG by 10 to 40 msec (",
"    <a class=\"graphic graphic_waveform graphicRef72398 \" href=\"UTD.htm?8/25/8598\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. If preexcitation is minimal in sinus rhythm, then atrial pacing can be performed to facilitate ventricular preexcitation by delaying AV nodal conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Left-sided accessory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;With left-sided accessory pathways, the multiple recording electrodes on the coronary sinus catheter will demonstrate eccentric retrograde atrial activation arising earliest on one pole of the coronary sinus catheter. Ideally, the earliest site should be flanked on either side by electrodes recording slightly later atrial activation, so-called \"bracketing\" of the earliest site. If the distal or proximal pole of the coronary sinus catheter records the earliest atrial activation, advancing or withdrawing the coronary sinus catheter by a few centimeters should allow bracketing of the retrograde atrial activation sequence.",
"   </p>",
"   <p>",
"    The earliest activation, occurring simultaneously at two adjacent coronary sinus recording sites, may result from a single pathway located between the two recording electrodes or two pathways with atrial insertions at the two recording electrodes (",
"    <a class=\"graphic graphic_figure graphicRef71684 \" href=\"UTD.htm?25/9/25749\">",
"     figure 1",
"    </a>",
"    ). Inserting or withdrawing the coronary sinus catheter by a few millimeters to determine the absolute earliest sites of activation, or placing the ablation catheter between the two poles of the coronary sinus catheter, can help distinguish the two possibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/11\">",
"     11",
"    </a>",
"    ]. It is important to recognize that, because the coronary sinus is located above the mitral annulus, recordings from the coronary sinus are not always representative of activation at the mitral annulus where the accessory pathway connects the atrium to the ventricle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Right-sided accessory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recording electrodes placed within the right coronary artery have been utilized to allow precise localization of right free wall pathways; a pull-back technique is used, in a fashion analogous to the coronary sinus pull-back for left-sided accessory pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/15\">",
"     15",
"    </a>",
"    ]. However, careful attention to mapping the tricuspid annulus, aided by specialized preformed sheaths to keep the deflectable catheters at the valve annulus rather than at the atrial reflection over the AV groove, generally circumvents the need for right coronary artery mapping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Septal accessory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anteroseptal, posteroseptal, and intermediate septal accessory pathways result in \"concentric\" retrograde atrial activation during orthodromic AV reciprocating tachycardia or ventricular pacing given their proximity to the AV node. If the recording poles of the coronary sinus catheter are pulled back to the coronary sinus ostium, activation at this site can be seen to precede atrial activation on the His bundle catheter when a posteroseptal accessory pathway is present. More precise mapping of septal accessory pathways depends upon detailed mapping with a roving catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mapping the atrial insertion of a septal pathway should be performed during AVRT rather than during ventricular pacing to avoid mapping of atrial activation due to preferential retrograde AV nodal conduction. This could result in inadvertent ablation of the AV node with consequent heart block. When sustained AVRT cannot be induced, ventricular pacing can be used, but the pacing rate must be rapid enough to prolong retrograde AV nodal conduction, thus allowing identification of eccentric retrograde atrial activation and avoiding fusion activation of the atria. This may not be possible with AV nodes that have rapid retrograde conduction, and may require pharmacologic block (eg, with adenosine).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Accessory pathway potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In either the anterograde or retrograde directions, discrete potentials can be seen bridging the atrial and ventricular electrograms at the site of the accessory pathway (",
"    <a class=\"graphic graphic_waveform graphicRef59861 \" href=\"UTD.htm?11/43/11954\">",
"     waveform 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/11,14,17-20\">",
"     11,14,17-20",
"    </a>",
"    ]. Such potentials are thought to be generated by the accessory pathways and can be shown to dynamically follow atrial and ventricular premature activation in a fashion parallel to accessory pathway function. Recording of accessory pathway potentials is a reliable means of directing radiofrequency current catheter ablation of the accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/14,17-20\">",
"     14,17-20",
"    </a>",
"    ]. This is also true for atriofascicular connections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Criteria for successful ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For anterogradely functioning accessory pathways, the presence of accessory pathway potentials (a local ventricular activation preceding onset of the surface delta wave by 30 to 40 msec) and a short interval between the accessory pathway potential and the ventricular electrogram are predictive of successful ablation and thus indicate the greatest proximity of the catheter to the accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For retrogradely functioning pathways, the presence of accessory pathway potentials, continuous electrical activity, and a short local VA interval during reciprocating tachycardia are most predictive of successful ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators have shown that additional information can be gained from recording unipolar electrograms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/20\">",
"     20",
"    </a>",
"    ]. If the unipolar electrode is situated at the site of ventricular insertion of an accessory pathway, then all ventricular activation conducts away from the electrode to generate a QS pattern ventricular electrogram following a short PQ segment, given the short accessory pathway activation time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/20\">",
"     20",
"    </a>",
"    ]. Identification of a QS complex may be even more important in localizing the ventricular insertion of accessory pathways that insert remotely from the AV groove, such as decremental atriofascicular or nodofascicular (Mahaim) pathways inserting into His-Purkinje fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17943?source=see_link\">",
"     \"Mahaim fiber tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Atrioventricular nodal reentrant tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular nodal reentrant tachycardia (AVNRT) generally occurs in patients who have dual AV nodal pathways: one pathway is capable of fast conduction, but has a relatively long refractory period, while the other pathway conducts slowly, but has a short refractory period. AVNRT may be the orthodromic, common or typical form (fast-slow) or antidromic, uncommon, or atypical form (slow-fast). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Common AVNRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the common or typical form of AVNRT (slow-fast), anterograde AV conduction occurs along the slow pathway and retrograde VA conduction occurs along the fast pathway. Identification of the fast pathway is based upon localization of the earliest site of retrograde atrial activation during AVNRT in an anteroseptal region near the His bundle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since atrial activation in the anterior septal region occurs concomitantly with or slightly before local ventricular activation, it is sometimes difficult to discern the atrial from the ventricular activation complex on the His bundle recording. Atrial mapping of the His bundle region can be facilitated by placing a relatively early premature ventricular activation during tachycardia to advance local ventricular septal activation, allowing distinction of the local atrial electrogram. The VA interval on the His bundle electrogram is ordinarily 0 to 20 msec before the His bundle electrogram during typical AVNRT at the site of successful fast pathway ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For typical AVNRT, ablation of the slow, posteriorly located, AV nodal pathway is associated with a lower incidence of heart block than ablation of the fast pathway, since the slow pathway is typically more remote from the compact AV node. Mapping of the earliest atrial activation during tachycardia, however, will localize the retrograde limb of the reentrant circuit, which is the fast pathway. Therefore, unlike AVRT and most other arrhythmias, mapping for ablation of typical AVNRT is performed during sinus rhythm. The electrogram during sinus rhythm at the site of the slow pathway is characterized by a low amplitude, fractionated atrial electrogram and is usually located just outside the superior aspect of the coronary sinus ostium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Uncommon AVNRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the uncommon or atypical form of AVNRT (slow-fast), anterograde AV conduction occurs along the fast pathway and retrograde VA conduction occurs along the slow pathway. During the atypical AVNRT or during ventricular pacing with retrograde conduction across the slow pathway, retrograde atrial activation occurs earliest at the coronary sinus ostial area (posteroseptal region). Mapping of the slow pathway of the AV node rests upon its spatial proximity to the coronary sinus ostium.",
"   </p>",
"   <p>",
"    During sinus rhythm, or an atrially paced rhythm, complex and fractionated atrial electrograms are seen in the posteroseptal space with discrete potentials, perhaps representing an activation potential from a discrete slow pathway or possibly representing complexities of conduction in the posterior AV nodal complex in a region critical for AV nodal reentry [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The observation that such \"slow pathway potentials\" occur in patients without AVNRT or dual AV nodal physiology suggests that such complex electrograms in the posteroseptal space represents the normal conduction characteristics of this area [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of its origin, the presence of complex and fractionated electrograms designates an area critical for the maintenance of AVNRT because ablation of this site prevents initiation of tachycardia, although dual AV nodal physiology may persist [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variants of AVNRT may be seen in which retrograde activation occurs in intermediate septal regions or within the os of the coronary sinus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardia is a relatively uncommon form of supraventricular tachycardia and can be due to macroreentry or can be focal in origin. Focal atrial tachycardia can be due to microreentry, triggered, or automatic mechanisms. A macroreentrant atrial tachycardia can often be distinguished from a focal atrial tachycardia by the observation that atrial depolarization can be recorded somewhere in the atria during the entire tachycardia cycle.",
"   </p>",
"   <p>",
"    The majority of atrial tachycardias arise within the right atrium and can be mapped and ablated via the usual approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. For mapping and ablation of left atrial tachycardia, a transseptal approach to the left atrium is usually utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The older technique of two-catheter mapping (\"leap-frog technique\") has been largely replaced by an advanced computerized mapping methodology, which has facilitated the mapping of both focal and macroreentrant tachycardias (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65810 graphicRef75508 graphicRef55564 \" href=\"UTD.htm?20/24/20873\">",
"     image 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/30\">",
"     30",
"    </a>",
"    ]. Dynamic isochronous activation maps generated by electroanatomic mapping and isopotential maps generated by composite noncontact mapping electrodes may greatly aid in the definition of the circuit underlying a macroreentrant atrial tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Automatic focal atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the tachycardia is focal in origin and does not involve an obvious macroreentrant circuit, activation mapping is performed by identifying the site of earliest atrial activation during tachycardia and confirming that there is centrifugal activation away from this site (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75508 graphicRef55564 \" href=\"UTD.htm?25/47/26357\">",
"     image 1B-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    .) Detailed mapping of the atrial activation sequence during tachycardia is performed using one or more mapping catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/1,27-29\">",
"     1,27-29",
"    </a>",
"    ]. In adults, local electrograms are frequently fractionated, of low amplitude, and are prolonged at the site of origin of atrial tachycardia (",
"    <a class=\"graphic graphic_waveform graphicRef66970 \" href=\"UTD.htm?19/1/19475\">",
"     waveform 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/1,28,29\">",
"     1,28,29",
"    </a>",
"    ].This finding may not be as common in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=see_link\">",
"     \"Catheter ablation of atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pace mapping has also been used for atrial tachycardia. The P wave morphology and the intraatrial activation sequence during atrial tachycardia and pacing from the mapping catheter are compared; if they are similar, the mapping catheter is presumably in close proximity to the site of origin of the atrial tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/29\">",
"     29",
"    </a>",
"    ]. However, pace mapping of the atria is complicated by difficulty of precise 12-lead ECG identification of P wave morphology during tachycardia because of frequent overlap of the P wave with the preceding QRST segment. As a result, pace mapping of the atria seems to add little additional benefit to activation mapping during the tachycardia, except when the atrial tachycardia is not inducible or not sustained for long enough durations to allow activation mapping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Macroreentrant atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with atrial tachycardia, especially those with structural heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prior cardiac surgery, have reentrant circuits in which the diastolic limb can be fully or partially mapped over one to several centimeters of myocardium. These tachycardias are called macroreentrant atrial tachycardias to distinguish them from focal atrial tachycardias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9368?source=see_link\">",
"     \"Intraatrial reentrant tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macroreentrant tachycardias require mapping of the entire reentrant circuit using roving catheter techniques or simultaneous recordings from multiple electrodes. Activation times are recorded at each site and the points registered on a display of the atria for graphic registration of the circuit. Pacing within the diastolic limb of the circuit may result in entrainment of the tachycardia without evidence of fusion of the P wave, so-called entrainment with concealed fusion. The amount of latency between the stimulus and the onset of the P wave during concealed entrainment is inversely proportionate to the distance from the exit site, ie, the shorter the stimulus to P wave latency, the closer to the exit site from the zone of slow conduction. Identification of sites that allow concealed entrainment and confirmation that they lie within the circuit by measurement of post-pacing intervals may allow a higher rate of successful ablation.",
"   </p>",
"   <p>",
"    The success of ablation in patients with repaired congenital heart disease, in whom multiple complex reentrant circuits are present, can be further improved by the combination of entrainment and electroanatomical mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/31\">",
"     31",
"    </a>",
"    ] or through the use of a noncontact endocardial mapping system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter may be of the typical or atypical type. Type I (typical or common atrial flutter) was separated from type II (uncommon or atypical atrial flutter) on the basis of rate, the ability to transiently entrain type I but not type II, and the observation that type II atrial flutter could change in a \"stepwise\" manner to type I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Common (type I) atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I atrial flutter is a macroreentrant atrial tachyarrhythmia with a reentrant circuit around an area of functional block located in the posterolateral right atrium along the crista terminalis (",
"    <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Earliest presystolic activity occurs in the region of the coronary sinus ostium and activation proceeds counterclockwise around the area of block. Electrograms obtained from the region of block occur throughout much of diastole and are markedly prolonged and fractionated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocardial mapping in the electrophysiology laboratory is generally performed with one or several right atrial catheters, including a halo catheter and a deflectable, exploring catheter. Activation maps must be subsequently generated from the individual site data to retrace the pattern of activation during typical atrial flutter. Nonfluoroscopic electroanatomic mapping is also an effective way to map atrial flutter.",
"   </p>",
"   <p>",
"    Successful ablation of atrial flutter requires the creation of conduction block through the cavotricuspid isthmus. This is usually accomplished by the delivery of sequential contiguous individual lesions that follow a line between the tricuspid annulus and the inferior vena cava. This line can be drawn anywhere between the coronary sinus ostium and the posterolateral tricuspid annulus (",
"    <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a successful ablation is performed during atrial flutter, the flutter will terminate. However, termination is not an adequate endpoint. To prevent recurrent atrial flutter, complete bidirectional conduction block must be achieved. This can be demonstrated by pacing from the coronary sinus and from the lateral tricuspid annulus and excluding transisthmus conduction. Advanced mapping systems have been used to assist in the determination of complete conduction block [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/39\">",
"     39",
"    </a>",
"    ]. Ablation of the cavotricuspid isthmus for typical atrial flutter can also be performed during sinus rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Uncommon (type II) atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncommon forms of atrial flutter (type II) have also been mapped in the electrophysiology laboratory; they represent macroreentrant circuits around large areas of presumed functional block, similar to typical atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/40\">",
"     40",
"    </a>",
"    ]. The macroreentrant circuit may simply be a clockwise variant of typical atrial flutter or may result from smaller macroreentrant circuits located in the right atrium, such as the lower loop circuit (lower half of the typical atrial flutter circuit) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/41\">",
"     41",
"    </a>",
"    ] or a circuit around a core of functional block in the crista terminalis area in the free lateral wall of the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/42\">",
"     42",
"    </a>",
"    ]. Figure of eight circuits have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/43\">",
"     43",
"    </a>",
"    ]. Type II atrial flutter arising in the left atrium is uncommon and usually occurs in patients with left heart disease and prior cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/44\">",
"     44",
"    </a>",
"    ]. The incidence of postablation left atrial flutter and atrial tachycardias has increased greatly as the number of patients undergoing catheter ablation for atrial fibrillation has increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike typical flutter, which can be ablated by an \"anatomic approach\" targeting the right atrial isthmus (ie, the tissue between the inferior vena cava and the tricuspid annulus), these atypical forms must be mapped individually in detail using activation sequence and entrainment techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation has been shown to be an effective treatment for some patients with atrial fibrillation (AF). A brief summary is included below; however, this topic is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to catheter ablation for AF, most of the mapping data regarding human AF was from multielectrode epicardial mapping during cardiac surgery. The mapping techniques that are currently used during endocardial, transvenous catheter ablation have evolved from bipolar recordings with a single catheter to multiple recordings with specialized catheters and advanced mapping techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link&amp;anchor=H19#H19\">",
"     \"Electrophysiologic cardiac mapping: Techniques\", section on 'Electroanatomical mapping'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link&amp;anchor=H21#H21\">",
"     \"Electrophysiologic cardiac mapping: Techniques\", section on 'Noncontact mapping'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two general approaches to ablation for AF have been developed: segmental ostial ablation and circumferential left atrial (LA) ablation. These two approaches use many of the same mapping techniques, although there are some differences. In the segmental approach, each PV is electrically isolated with sequential ablation at sites of conduction between the LA and PV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/45\">",
"     45",
"    </a>",
"    ]. Ablation targets are identified by positioning a circular mapping catheter (\"lasso\" catheter) or a multielectrode basket catheter at the PV ostium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast, circumferential LA ablation is based primarily on anatomic landmarks, usually defined by electroanatomic maps. In this procedure, the location of PV ostia is defined and confluent ablation lesions are placed to encircle the ostia, usually in two pairs.",
"   </p>",
"   <p>",
"    These approaches are not mutually exclusive. Electroanatomic mapping is usually done in segmental ostial ablation procedures, and variations of this approach have been developed in which lesions placement at the atrial side of the",
"    <span class=\"nowrap\">",
"     LA/PV",
"    </span>",
"    junction is guided by theses electroanatomic maps [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H5#H5\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Pulmonary vein isolation procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H12#H12\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Circumferential left atrial ablation or WACA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Persistent or permanent atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In persistent or permanent atrial fibrillation (AF), successful ablation can be more difficult, particularly in patients with more advanced structural heart disease. In such patients, in addition to the triggering influence of ectopic beats, AF may be perpetuated by abnormal substrate in the diseased atria. Information regarding the mechanisms of persistent AF in these patients has been obtained from simultaneous biatrial endocardial mapping using large multielectrode basket catheters placed in each atria, and by noncontact mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For persistent AF, alternative mapping and ablation techniques are being investigated, and often include additional left atrial linear lesions. High-frequency fractionated electrograms can often be recorded at atrial sites in patients with persistent AF. These sites may represent rotors that are involved in the perpetuation of AF. These areas have been identified using visual analysis of the electrograms during electroanatomic mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/50\">",
"     50",
"    </a>",
"    ] and by using techniques that involve automated dominant frequency analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/51\">",
"     51",
"    </a>",
"    ]. Special catheters with spoke-like extensions also may be useful during mapping to identify areas of focal discharge with radial spread that may represent drivers during AF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mapping of ventricular tachycardia (VT) in the electrophysiology laboratory utilizes the same steerable mapping catheters as used for the mapping and ablation of supraventricular tachycardias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=see_link\">",
"     \"Surgery for ventricular tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several means of localizing the site of origin of a VT have been developed; these include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pace mapping (",
"      <a class=\"graphic graphic_waveform graphicRef68142 graphicRef79938 \" href=\"UTD.htm?38/21/39258\">",
"       waveform 4A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Activation mapping to identify the site of earliest activation during VT",
"     </li>",
"     <li>",
"      Entrainment mapping during tachycardia",
"     </li>",
"     <li>",
"      Identification of areas of fractionated conduction and low-voltage electrograms during sinus or atrially-paced rhythm",
"     </li>",
"     <li>",
"      Identification of slowly-conducting regions during \"electrical diastole\" by noncontact isopotential mapping",
"     </li>",
"     <li>",
"      Electroanatomic mapping (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56674 \" href=\"UTD.htm?28/60/29632\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Noncontact endocardial activation mapping (",
"      <a class=\"graphic graphic_figure graphicRef77090 \" href=\"UTD.htm?29/58/30627\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal endocardial mapping technique for ischemic VT remains to be defined. Not infrequently all of the above techniques, or a combination of several, are used to correctly define the site of origin of the VT. Advanced mapping systems are useful to define the critical part of a reentrant circuit. With currently available technologies, catheter ablation for VT with an endocardial approach is successful in 70 to 80 percent of patients with structural heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Epicardial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a subset of patients in whom an endocardial approach is unsuccessful, the critical portion of the arrhythmia circuit may be located epicardially [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27305/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Ventricular tachycardia (VT) which cannot be successfully mapped by an endocardial approach, suggesting an epicardial origin, appears to be more common in patients with a nonischemic dilated cardiomyopathy.",
"   </p>",
"   <p>",
"    The pericardial space can be accessed using a percutaneous subxiphoid approach, or surgically via a small subxiphoid pericardial window. The epicardial surface of the left ventricle can be mapped after access is obtained using a standard steerable ablation catheter. Ablation targets can be selected using the same methods used endocardially to localize the VT site of origin as described above.",
"   </p>",
"   <p>",
"    Epicardial mapping has also been described during ablation of other arrhythmias, including epicardial accessory pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link&amp;anchor=H21#H21\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\", section on 'Epicardial ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8319343\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac mapping identifies the temporal and spatial distributions of electrical potentials generated by the myocardium during normal or abnormal rhythms. It is commonly used to identify the site of origin or a critical area of conduction for an arrhythmia in order to allow for ablation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preexcitation syndromes &mdash; Cardiac mapping is used to locate the atrial and ventricular insertion sites of accessory pathways responsible for preexcitation syndromes. To determine the atrial insertion site, the earliest site of retrograde atrial activation during orthodromic atrioventricular (AV) reciprocating tachycardia (AVRT) or ventricular pacing must be identified. The assumption is that the local retrograde ventriculoatrial (VA) interval on the recording electrode will be shortest at the atrial insertion site. More precise localization of the ventricular insertion site is obtained by mapping along the AV groove in sinus rhythm to determine the site of earliest ventricular activation during preexcited beats. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preexcitation syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrioventricular nodal reentrant tachycardia (AVNRT) &mdash; For typical AVNRT, ablation of the slow, posteriorly located, AV nodal pathway is associated with a lower incidence of heart block than ablation of the fast pathway, since the slow pathway is typically more remote from the compact AV node. Mapping of the earliest atrial activation during tachycardia, however, will localize the retrograde limb of the reentrant circuit, which is the fast pathway. Therefore, unlike AVRT and most other arrhythmias, mapping for ablation of typical AVNRT is performed during sinus rhythm. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Atrioventricular nodal reentrant tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial tachycardia &mdash; Atrial tachycardia is a relatively uncommon form of supraventricular tachycardia and can be due to macroreentry or can be focal in origin. The majority of atrial tachycardias arise within the right atrium and can be mapped and ablated via the usual approach. For mapping and ablation of left atrial tachycardia, a transseptal approach to the left atrium is usually utilized. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Atrial tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial flutter &mdash; Type I atrial flutter is a macroreentrant atrial tachyarrhythmia with a reentrant circuit around an area of functional block located in the posterolateral right atrium along the crista terminalis. Successful ablation requires the creation of conduction block through the cavotricuspid isthmus. When a successful ablation is performed during atrial flutter, the flutter will terminate. However, to prevent recurrent atrial flutter, complete bidirectional conduction block must be achieved. Type II atrial flutter is less common and cannot be ablated by an anatomic approach; each case must be mapped individually in detail. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Atrial flutter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial fibrillation &mdash; There are two general approaches to the ablation for atrial fibrillation (AF): segmental ostial ablation and circumferential left atrial ablation. These two approaches use many of the same mapping techniques and are not mutually exclusive. In persistent or permanent AF, successful ablation can be more difficult, particularly in patients with more advanced structural heart disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular tachycardia &mdash; Mapping of ventricular tachycardia (VT) in the electrophysiology laboratory utilizes the same steerable mapping catheters as used for the mapping and ablation of supraventricular tachycardias. The mapping technique for scar-mediated VT depends on whether or not the VT is hemodynamically stable and well tolerated. When the patient can tolerate being in sustained monomorphic VT, mapping techniques to identify an ablation target include activation and entrainment mapping. For hemodynamically unstable or nonsustained VT, mapping must be done during sinus rhythm to determine the exit site of the VT or a critical portion of the circuit. These techniques include identification of areas of scar and mid-diastolic potentials during sinus rhythm, and pace-mapping. Focal VT, such as RVOT VT, can be mapped using activation mapping, or pacemapping when the VT is difficult to induce. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Ventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a subset of patients in whom an endocardial approach is unsuccessful, the critical portion of the arrhythmia circuit may be located epicardially using a percutaneous subxiphoid approach, or surgically via a small subxiphoid pericardial window. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Epicardial approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/1\">",
"      Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation 1994; 89:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/2\">",
"      Schilling RJ, Davies DW, Peters NS. Clinical developments in cardiac activation mapping. Eur Heart J 2000; 21:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/3\">",
"      Breithardt G, Borggrefe M, Wichter T. Catheter ablation of idiopathic right ventricular tachycardia. Circulation 1990; 82:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/4\">",
"      Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991; 324:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/5\">",
"      Calkins H, Kalbfleisch SJ, el-Atassi R, et al. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol 1993; 71:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/6\">",
"      Gepstein L, Hayam G, Ben-Haim SA. A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart. In vitro and in vivo accuracy results. Circulation 1997; 95:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/7\">",
"      Ben-Haim SA, Osadchy D, Schuster I, et al. Nonfluoroscopic, in vivo navigation and mapping technology. Nat Med 1996; 2:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/8\">",
"      Khoury DS, Taccardi B, Lux RL, et al. Reconstruction of endocardial potentials and activation sequences from intracavitary probe measurements. Localization of pacing sites and effects of myocardial structure. Circulation 1995; 91:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/9\">",
"      Chen SA, Tai CT. Ablation of atrioventricular accessory pathways: current technique-state of the art. Pacing Clin Electrophysiol 2001; 24:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/10\">",
"      Crossen KJ, Lindsay BD, Cain ME. Reliability of retrograde atrial activation patterns during ventricular pacing for localizing accessory pathways. J Am Coll Cardiol 1987; 9:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/11\">",
"      Jackman WM, Friday KJ, Yeung-Lai-Wah JA, et al. New catheter technique for recording left free-wall accessory atrioventricular pathway activation. Identification of pathway fiber orientation. Circulation 1988; 78:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/12\">",
"      Denes P, Wyndham CR, Amat-y-Leon F, et al. Atrial pacing at multiple sites in the Wolff-Parkinson-White syndrome. Br Heart J 1977; 39:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/13\">",
"      Mitchell LB, Mason JW, Scheinman MM, et al. Recordings of basal ventricular preexcitation from electrode catheters in patients with accessory atrioventricular connections. Circulation 1984; 69:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/14\">",
"      Chen X, Borggrefe M, Shenasa M, et al. Characteristics of local electrogram predicting successful transcatheter radiofrequency ablation of left-sided accessory pathways. J Am Coll Cardiol 1992; 20:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/15\">",
"      Lesh MD, Van Hare GF, Schamp DJ, et al. Curative percutaneous catheter ablation using radiofrequency energy for accessory pathways in all locations: results in 100 consecutive patients. J Am Coll Cardiol 1992; 19:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/16\">",
"      Epstein AE, Kirklin JK, Holman WL, et al. Intermediate septal accessory pathways: electrocardiographic characteristics, electrophysiologic observations and their surgical implications. J Am Coll Cardiol 1991; 17:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/17\">",
"      Calkins H, Kim YN, Schmaltz S, et al. Electrogram criteria for identification of appropriate target sites for radiofrequency catheter ablation of accessory atrioventricular connections. Circulation 1992; 85:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/18\">",
"      Jackman WM, Friday KJ, Scherlag BJ, et al. Direct endocardial recording from an accessory atrioventricular pathway: localization of the site of block, effect of antiarrhythmic drugs, and attempt at nonsurgical ablation. Circulation 1983; 68:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/19\">",
"      Kuck KH, Schl&uuml;ter M. Single-catheter approach to radiofrequency current ablation of left-sided accessory pathways in patients with Wolff-Parkinson-White syndrome. Circulation 1991; 84:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/20\">",
"      Ha&iuml;ssaguerre M, Dartigues JF, Warin JF, et al. Electrogram patterns predictive of successful catheter ablation of accessory pathways. Value of unipolar recording mode. Circulation 1991; 84:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/21\">",
"      Kottkamp H, Hindricks G, Shenasa H, et al. Variants of preexcitation--specialized atriofascicular pathways, nodofascicular pathways, and fasciculoventricular pathways: electrophysiologic findings and target sites for radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1996; 7:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/22\">",
"      Sung RJ, Waxman HL, Saksena S, Juma Z. Sequence of retrograde atrial activation in patients with dual atrioventricular nodal pathways. Circulation 1981; 64:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/23\">",
"      Haissaguerre M, Warin JF, Lemetayer P, et al. Closed-chest ablation of retrograde conduction in patients with atrioventricular nodal reentrant tachycardia. N Engl J Med 1989; 320:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/24\">",
"      Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 1992; 327:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/25\">",
"      Haissaguerre M, Gaita F, Fischer B, et al. Elimination of atrioventricular nodal reentrant tachycardia using discrete slow potentials to guide application of radiofrequency energy. Circulation 1992; 85:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/26\">",
"      Hazlitt HA, Beckman KJ, McClelland JH, et al. Prevalence of slow AV nodal pathway potentials in patients without AV nodal reentrant tachycardia. J Am Coll Cardiol 1993; 21:281A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/27\">",
"      Walsh EP, Saul JP, Hulse JE, et al. Transcatheter ablation of ectopic atrial tachycardia in young patients using radiofrequency current. Circulation 1992; 86:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/28\">",
"      Kay GN, Chong F, Epstein AE, et al. Radiofrequency ablation for treatment of primary atrial tachycardias. J Am Coll Cardiol 1993; 21:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/29\">",
"      Tracy CM, Swartz JF, Fletcher RD, et al. Radiofrequency catheter ablation of ectopic atrial tachycardia using paced activation sequence mapping. J Am Coll Cardiol 1993; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/30\">",
"      Hoffmann E, Nimmermann P, Reithmann C, et al. New mapping technology for atrial tachycardias. J Interv Card Electrophysiol 2000; 4 Suppl 1:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/31\">",
"      Delacretaz E, Ganz LI, Soejima K, et al. Multi atrial maco-re-entry circuits in adults with repaired congenital heart disease: entrainment mapping combined with three-dimensional electroanatomic mapping. J Am Coll Cardiol 2001; 37:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/32\">",
"      Paul T, Windhagen-Mahnert B, Kriebel T, et al. Atrial reentrant tachycardia after surgery for congenital heart disease: endocardial mapping and radiofrequency catheter ablation using a novel, noncontact mapping system. Circulation 2001; 103:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/33\">",
"      Disertori M, Inama G, Vergara G, et al. Evidence of a reentry circuit in the common type of atrial flutter in man. Circulation 1983; 67:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/34\">",
"      Cosio FG, Arribas F, Barbero JM, et al. Validation of double-spike electrograms as markers of conduction delay or block in atrial flutter. Am J Cardiol 1988; 61:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/35\">",
"      Olshansky B, Okumura K, Hess PG, Waldo AL. Demonstration of an area of slow conduction in human atrial flutter. J Am Coll Cardiol 1990; 16:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/36\">",
"      Feld GK, Fleck RP, Chen PS, et al. Radiofrequency catheter ablation for the treatment of human type 1 atrial flutter. Identification of a critical zone in the reentrant circuit by endocardial mapping techniques. Circulation 1992; 86:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/37\">",
"      Cosio FG, Arribas F, Palacios J, et al. Fragmented electrograms and continuous electrical activity in atrial flutter. Am J Cardiol 1986; 57:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/38\">",
"      Cosio FG, L&oacute;pez-Gil M, Goicolea A, et al. Radiofrequency ablation of the inferior vena cava-tricuspid valve isthmus in common atrial flutter. Am J Cardiol 1993; 71:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/39\">",
"      Lin YJ, Tai CT, Huang JL, et al. Characteristics of virtual unipolar electrograms for detecting isthmus block during radiofrequency ablation of typical atrial flutter. J Am Coll Cardiol 2004; 43:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/40\">",
"      Cosio FG, Goicolea A, L&oacute;pez-Gil M, et al. Atrial endocardial mapping in the rare form of atrial flutter. Am J Cardiol 1990; 66:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/41\">",
"      Cheng J, Cabeen WR Jr, Scheinman MM. Right atrial flutter due to lower loop reentry: mechanism and anatomic substrates. Circulation 1999; 99:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/42\">",
"      Kall JG, Rubenstein DS, Kopp DE, et al. Atypical atrial flutter originating in the right atrial free wall. Circulation 2000; 101:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/43\">",
"      Tai CT, Liu TY, Lee PC, et al. Non-contact mapping to guide radiofrequency ablation of atypical right atrial flutter. J Am Coll Cardiol 2004; 44:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/44\">",
"      Ja&iuml;s P, Shah DC, Ha&iuml;ssaguerre M, et al. Mapping and ablation of left atrial flutters. Circulation 2000; 101:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/45\">",
"      Arentz T, von Rosenthal J, Blum T, et al. Feasibility and safety of pulmonary vein isolation using a new mapping and navigation system in patients with refractory atrial fibrillation. Circulation 2003; 108:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/46\">",
"      Knight BP, Oral H, Morady F. Images in cardiovascular medicine. Paroxysmal fibrillation within an isolated pulmonary vein. Circulation 2002; 106:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/47\">",
"      Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000; 102:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/48\">",
"      Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 2002; 105:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/49\">",
"      Lemery R. Bi-atrial mapping of atrial arrhythmias. Card Electrophysiol Rev 2002; 6:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/50\">",
"      Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/51\">",
"      Sanders P, Berenfeld O, Hocini M, et al. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation 2005; 112:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/52\">",
"      Sanders P, Hocini M, Ja&iuml;s P, et al. Characterization of focal atrial tachycardia using high-density mapping. J Am Coll Cardiol 2005; 46:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/53\">",
"      Delacretaz E, Stevenson WG. Catheter ablation of ventricular tachycardia in patients with coronary heart disease: part I: Mapping. Pacing Clin Electrophysiol 2001; 24:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/54\">",
"      Bogun F, Knight B, Goyal R, et al. Clinical value of the postpacing interval for mapping of ventricular tachycardia in patients with prior myocardial infarction. J Cardiovasc Electrophysiol 1999; 10:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/55\">",
"      Sosa E, Scanavacca M. Epicardial mapping and ablation techniques to control ventricular tachycardia. J Cardiovasc Electrophysiol 2005; 16:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/56\">",
"      Desai AD, Burke MC, Hong TE, et al. Termination of epicardial left ventricular tachycardia by pacing without global capture. J Cardiovasc Electrophysiol 2005; 16:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27305/abstract/57\">",
"      Schweikert RA, Saliba WI, Tomassoni G, et al. Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations. Circulation 2003; 108:1329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1024 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27305=[""].join("\n");
var outline_f26_42_27305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8319343\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAPPING OF SPECIFIC TACHYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preexcitation syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Left-sided accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Right-sided accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Septal accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Accessory pathway potentials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Criteria for successful ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Atrioventricular nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Common AVNRT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Uncommon AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Automatic focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Macroreentrant atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Common (type I) atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Uncommon (type II) atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Persistent or permanent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Epicardial approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8319343\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1024|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/21/7508\" title=\"diagnostic image 1A\">",
"      Electroanatomic atrial tachy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/15/8433\" title=\"diagnostic image 1B\">",
"      Electroanatomic atrial tachy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/19/2352\" title=\"diagnostic image 1C\">",
"      Map ectopic atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/60/29632\" title=\"diagnostic image 2\">",
"      Electroanatomic mapping VT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1024|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/9/25749\" title=\"figure 1\">",
"      Electrograms dual pathways WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/10/27811\" title=\"figure 2\">",
"      Flutter circuit right atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/58/30627\" title=\"figure 3\">",
"      Bipolar mapping NSR VT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1024|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/25/8598\" title=\"waveform 1\">",
"      EP study tracings preablation mapping WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/43/11954\" title=\"waveform 2\">",
"      Electrograms AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/1/19475\" title=\"waveform 3\">",
"      Electrograms atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?18/4/18503\" title=\"waveform 4A\">",
"      ECG pace mapping RVOT tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/26/41385\" title=\"waveform 4B\">",
"      ECG pace map ventricular tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=related_link\">",
"      Catheter ablation of atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9368?source=related_link\">",
"      Intraatrial reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17943?source=related_link\">",
"      Mahaim fiber tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=related_link\">",
"      Surgery for ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_42_27306="Clinical manifestations of Sjgren's syndrome: Extraglandular disease";
var content_f26_42_27306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Robert Fox, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Paul Creamer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Samuel L Moschella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/42/27306/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/42/27306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren&rsquo;s syndrome (SS) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function. SS occurs in a primary form not associated with other diseases and in a secondary form that complicates other rheumatic conditions, with the most common being rheumatoid arthritis.",
"   </p>",
"   <p>",
"    In primary or secondary SS, decreased exocrine gland function leads to the &ldquo;sicca complex,&rdquo; a combination of dry eyes (xerophthalmia) and dry mouth (xerostomia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, a variety of other disease manifestations can occur in SS. The clinical manifestations of SS are divided into the exocrine gland features and the extraglandular disease features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extraglandular disease manifestations and prognosis of SS will be reviewed here. The exocrine manifestations, diagnosis, distinctions between primary and secondary SS, and treatment of both sicca and extraglandular manifestations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=see_link\">",
"     \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=see_link\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTRAGLANDULAR ORGAN INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the exocrine glands, many other organs can be involved in patients with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/3\">",
"     3",
"    </a>",
"    ]. Typical but rarely diagnostic disease manifestations can be found in the following organs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin",
"     </li>",
"     <li>",
"      Joints and muscles",
"     </li>",
"     <li>",
"      Thyroid gland",
"     </li>",
"     <li>",
"      Lungs",
"     </li>",
"     <li>",
"      Heart",
"     </li>",
"     <li>",
"      Gastrointestinal tract",
"     </li>",
"     <li>",
"      Liver",
"     </li>",
"     <li>",
"      Kidneys",
"     </li>",
"     <li>",
"      Bladder",
"     </li>",
"     <li>",
"      Pancreas",
"     </li>",
"     <li>",
"      Peripheral nervous system",
"     </li>",
"     <li>",
"      Brain",
"     </li>",
"     <li>",
"      Lymph nodes and bone marrow (lymphoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A series of different classification criteria has been used to define and characterize SS. Most information cited in this topic review regarding SS has relied upon the 2002 American European Consensus Group (AECG) classification criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, in 2012, a different set of criteria was proposed by the American College of Rheumatology (ACR) that differed from the AECG criteria in several respects, including the exclusion of subjective ocular or oral dryness from the ACR criteria set and the lack of a distinction between primary and secondary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, differences in estimates of the frequency and severity of various clinical manifestations may be observed that depend upon the criteria used to identify the patients included in the analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H23#H23\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, a cohort of 886 patients meeting AECG criteria for primary SS were compared with patients also considered as having SS but lacking sufficient objective features to meet such criteria; among the patients meeting criteria, the features that were more common included hypergammaglobulinemia, low complement C4 levels, hematologic manifestations (leukopenia, anemia, and thrombocytopenia), and cutaneous vasculitis. However, the prevalence of thyroid, liver, and kidney disease was lower than reported in previous studies.",
"   </p>",
"   <p>",
"    The diagnosis of primary SS in a pregnant woman also has substantial potential implications for the fetus and newborn that must be considered during gestation and after delivery. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic abnormalities are prominent in many patients with SS. Because certain serologic findings correlate highly with specific clinical features and may contribute directly in some cases to the phenotype of individual patients, the serologic abnormalities commonly observed in SS are discussed briefly before a review of organ system involvement.",
"   </p>",
"   <p>",
"    The following serologic findings were observed in a cohort of 400 patients with primary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antinuclear antibodies (ANA) &mdash; 74 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-Ro/SSA",
"      </span>",
"      antibodies &mdash; 40 percent",
"     </li>",
"     <li>",
"      Rheumatoid factor (RF) &mdash; 38 percent",
"     </li>",
"     <li>",
"      Antismooth muscle antibodies &mdash; 35 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-La/SSB",
"      </span>",
"      antibodies &mdash; 26 percent",
"     </li>",
"     <li>",
"      Antiparietal cell gastric antibodies &mdash; 20 percent",
"     </li>",
"     <li>",
"      Antiperoxidase antibodies &mdash; 18 percent",
"     </li>",
"     <li>",
"      Antithyroglobulin antibodies &mdash; 13 percent",
"     </li>",
"     <li>",
"      Low CH50 &mdash; 12 percent",
"     </li>",
"     <li>",
"      Low C4 &mdash; 8 percent",
"     </li>",
"     <li>",
"      Cryoglobulinemia &mdash; 9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many serologic findings correlate with a higher risk of developing lymphoma. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Antinuclear antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;SS patients who have antinuclear antibodies (ANA) have a higher prevalence of adenopathy, Raynaud phenomenon, and cutaneous vasculitis compared with those who are ANA negative [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anti-Ro/SSA and anti-La/SSB antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with antibodies to these extractable nuclear antigens are more likely to have adenopathy, peripheral neuropathy, cutaneous vasculitis, Raynaud phenomenon, and annular erythema than are patients without these antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"     8",
"    </a>",
"    ]. However, photosensitivity is infrequent in these patients who have SS, unlike those who have systemic lupus erythematosus (SLE). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cutaneous vasculitis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link&amp;anchor=H11717369#H11717369\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\", section on 'Sj&ouml;gren&rsquo;s syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Anti-alpha-fodrin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to alpha-fodrin have been identified in patients with primary and secondary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Understanding of the epidemiology of these autoantibodies, their significance in the pathophysiology of SS, and their implications for extraglandular manifestations remain incomplete. Anti-alpha-fodrin antibodies were not measured in most large series of SS patients reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 90 SS patients (62 with primary SS and 28 with secondary SS), anti-alpha-fodrin antibodies were found in the following distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary SS &mdash; 35 and 31 percent had IgA and IgG, respectively.",
"     </li>",
"     <li>",
"      Secondary SS &mdash; 29 and 21 percent had IgA and IgG, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some data suggest that anti-alpha-fodrin antibodies are useful indicators of disease activity in patients with SS of short duration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25162?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of Sj&ouml;gren's syndrome\", section on 'Anti-alpha-fodrin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cryoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cryoglobulinemia have a high prevalence of parotidomegaly, adenopathy, cutaneous vasculitis, peripheral neuropathy, and Raynaud phenomenon compared with patients without cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypergammaglobulinemia and hypogammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypergammaglobulinemia, which may be either polyclonal or monoclonal (see below), has been described in a number of reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], with the prevalence being 22 percent in a series of 380 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"     11",
"    </a>",
"    ]. Hypergammaglobulinemia may account for some cases of elevated erythrocyte sedimentation rates in SS that occur in the absence of infection, systemic vasculitis, or other apparent causes.",
"   </p>",
"   <p>",
"    In the review of 380 patients, hypogammaglobulinemia was observed in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"     11",
"    </a>",
"    ]. The development of hypogammaglobulinemia in a patient with SS may be a harbinger of the development of lymphoma. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Monoclonal gammopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal gammopathies occur in patients with SS, being detected in 22 percent of patients in whom immunoelectrophoresis was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"     11",
"    </a>",
"    ]. IgG followed by IgM were the most common classes detected.",
"   </p>",
"   <p>",
"    The presence of a monoclonal gammopathy in SS usually correlates with the presence of cryoglobulins. Mixed cryoglobulinemia and monoclonal rheumatoid factor may identify patients with an increased risk for the development of a B-cell lymphoma (6 of 18 in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/14\">",
"     14",
"    </a>",
"    ]. However, in the larger series of 380 patients, the incidence of lymphoma was not different in patients with or without a monoclonal gammopathy (3 to 4 percent at a mean follow-up of 76 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The triad of cryoglobulinemia, hypocomplementemia, and purpura correlates strongly with severe disease complications and death [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple cutaneous syndromes may be associated with SS. The major skin findings include xerosis, cutaneous vasculitis, Raynaud phenomenon, and annular erythema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Xerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cutaneous symptoms of SS are dryness and its sequela, pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. Xerosis is characterized by dry, scaly skin, most often affecting the lower extremities and axillary creases. It appears linked to a specific alteration in the protective function of the skin&rsquo;s outer layer, the stratum corneum, rather than to decreased sebaceous or sweat gland secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors associated with xerosis include older age, frequent bathing, and low humidity. Symptoms tend to be worse in the winter in cold climates. The cornerstone of therapy for xerosis is the maintenance of adequate skin moisture with topical emollients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cutaneous vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous vasculitis occurs in approximately 10 percent of patients with SS. The development of cutaneous vasculitis may have important prognostic implications. As an example, SS patients with cutaneous vasculitis are more likely than those who do not have vasculitis to develop extraglandular manifestations, including lymphoma, and to die of disease-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11,21,22\">",
"     11,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the great majority of cases, cutaneous vasculitis in SS involves small blood vessels the size of capillaries, arterioles, and venules, leading to clinical manifestations typical of small vessel vasculitis. Palpable purpura is the most common sign, but urticarial lesions, macules, papules, and small ulcerated areas also occur. The typical distribution of these lesions is over the lower extremities. However, urticarial lesions are occasionally seen over the arms, the trunk, or even the face [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link&amp;anchor=H8#H8\">",
"     \"Hypersensitivity vasculitis in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the frequency with which cutaneous vasculitis in SS is associated with antibodies to the",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"     8",
"    </a>",
"    ], this complication of SS may be difficult to distinguish from the benign hyperglobulinemic purpura of Waldenstr&ouml;m [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. This latter entity is characterized by long-standing purpuric lesions (usually on the lower extremities), an elevated erythrocyte sedimentation rate, anemia, leukopenia, hyperglobulinemia, and antibodies to the",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    antigen. In many cases, hyperglobulinemic purpura of Waldenstr&ouml;m probably represents undiagnosed SS with cutaneous manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of cases of cutaneous vasculitis in SS are associated with leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Most such patients have involvement of small blood vessels, but medium-sized vessels are affected in up to 5 percent of cases with cutaneous vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"     11",
"    </a>",
"    ]. Necrotizing lesions are common in cutaneous vasculitis, regardless of whether the process is focused upon small- or medium-sized blood vessels or both (",
"    <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"UTD.htm?7/58/8106\">",
"     picture 1A-B",
"    </a>",
"    ). Lymphocytic vasculitis has also been reported in a small percentage of cases. The pathologic findings are usually confined to the upper dermis unless medium-sized muscular arterioles and arteries are involved.",
"   </p>",
"   <p>",
"    The minority of patients with medium-sized vessel disease can develop large cutaneous ulcers, and internal organ involvement that mimics polyarteritis nodosa or rheumatoid vasculitis may coexist. SS patients who develop this type of vascular involvement usually have cryoglobulins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\", section on 'Skin disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\", section on 'Cutaneous vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud phenomenon has been reported in 13 to 30 percent of patients with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. It may be associated with pulmonary fibrosis, arthritis, vasculitis, and antinuclear antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Annular erythema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photosensitivity and annular erythematous lesions that are identical to those of subacute cutaneous lupus erythematosus may occur in SS patients (",
"    <a class=\"graphic graphic_picture graphicRef54141 \" href=\"UTD.htm?13/32/13825\">",
"     picture 2",
"    </a>",
"    ). Many of these patients do not meet American College of Rheumatology criteria for lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/27\">",
"     27",
"    </a>",
"    ]. The lesions are polycyclic and maculopapular in nature and are invariably associated with antibodies to the",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     La/SSB",
"    </span>",
"    antigens. The sites affected tend to be the face, upper extremities, and trunk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H7#H7\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Subacute cutaneous lupus erythematosus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other cutaneous manifestations may occur in SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/3,28\">",
"     3,28",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythema nodosum",
"     </li>",
"     <li>",
"      Livedo reticularis",
"     </li>",
"     <li>",
"      Lichen planus",
"     </li>",
"     <li>",
"      Vitiligo",
"     </li>",
"     <li>",
"      Cutaneous amyloidosis",
"     </li>",
"     <li>",
"      Granuloma annulare",
"     </li>",
"     <li>",
"      Angular cheilitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;SS may be associated with both joint and muscle manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of patients with primary SS complain of arthralgia, with or without evidence of arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/29\">",
"     29",
"    </a>",
"    ]. The arthropathy is usually symmetric, is intermittent, and affects hands and knees. Joint disease in SS is typically nonerosive and nondeforming.",
"   </p>",
"   <p>",
"    Rheumatoid factor is reported in approximately 40 percent of patients with SS and is associated with a significantly higher prevalence of articular symptoms (45 versus 33 percent without articular complaints) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"     8",
"    </a>",
"    ]. Anticyclic citrullinated peptide antibodies are much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Serologic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild inflammatory myopathy characterized by the insidious onset of proximal muscle weakness may occur in SS. The frequency with which muscle disturbances are found depends upon how thoroughly the findings are sought, and the reported incidence ranges from 2.5 to 47 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, some asymptomatic patients have an inflammatory cell infiltrate on muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/12\">",
"     12",
"    </a>",
"    ]. Significant muscle weakness and dramatic muscle enzyme elevations combined with sicca symptoms raise the specter of SS occurring in the setting of an overlap connective tissue disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"     \"Clinical manifestations of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether thyroid disease is more common in patients with SS is controversial. Various series have found some form of structural, hormonal, or thyroid autoantibody abnormality in 10 to 70 percent of patients with primary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/12,32-34\">",
"     12,32-34",
"    </a>",
"    ]. In addition, autoimmune diseases, particularly autoimmune thyroid disease, tend to aggregate in the first degree relatives of patients with primary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with SS, being older and predominantly female, have a higher incidence of thyroid disease than the general population. Among 506 cases of primary SS reported in the medical literature from 1980 to 2000, the prevalence of hypothyroidism, hyperthyroidism, or any thyroid disease was 17, 6, and 29 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/36\">",
"     36",
"    </a>",
"    ]. However, in a well-designed study of 160 patients with primary SS, there was no statistically significant difference in the overall prevalence of thyroid disease or of any particular type of thyroid disease between cases and the age and sex-matched controls (36 and 27 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease, the most common pulmonary abnormality in SS, is often asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/37\">",
"     37",
"    </a>",
"    ]. Interstitial lung disease and related pulmonary manifestations of SS are discussed briefly here and in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=see_link\">",
"     \"Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the older literature, the term &ldquo;lymphocytic interstitial pneumonitis&rdquo; (LIP) was used to describe this pulmonary complication of SS. In more recent terminology, LIP is considered a subset of nonspecific interstitial pneumonitis (NSIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/38\">",
"     38",
"    </a>",
"    ]. LIP is characterized histologically by interstitial infiltration with polyclonal lymphocytes and plasma cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=see_link\">",
"     \"Lymphoid interstitial pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased incidence of subclinical SS has been observed in patients with interstitial lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High resolution computed tomography (CT) scanning reveals some pulmonary abnormality in a majority of patients with primary and secondary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/40\">",
"     40",
"    </a>",
"    ]. Basilar and subpleural sites are affected most often, typically with interstitial changes and ground glass opacities. A pattern suggestive of bronchiolitis, ascribed to the filling of small centrilobular bronchioles with pus, mucus, granulomas, or inflammatory cells and leading to air trapping, is less common than interstitial lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34633?source=see_link\">",
"     \"Respiratory bronchiolitis-associated interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enlarged lymph nodes of the lung or other evidence of lymphoproliferative disease involving the upper airways is generally confined to patients with primary SS. In addition, the importance of pulmonary lymphoid structures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/41\">",
"     41",
"    </a>",
"    ] has been recognized as part of the &ldquo;extranodal&rdquo; lymphoid infiltrates that were initially recognized as mucosa associated lymphoid tumors (MALT lymphomas) in the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Lymphoma'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of high endothelial venules in directing lymphocytes to extranodal sites including the lung, the gastrointestinal tract, the lacrimal and salivary glands, and, perhaps, the central nervous system is increasingly recognized as an important part of pathogenesis and as a target for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis is a rare complication of primary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], but echocardiographic evidence of prior pericarditis is more common. In an echocardiographic study of 150 patients with definite or probable SS, one-third had increased pericardial echogenicity suggestive of prior pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/46\">",
"     46",
"    </a>",
"    ]. Left ventricle hypokinesis is common among SS patients with a history of pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. However, the clinical significance of this finding is not clear.",
"   </p>",
"   <p>",
"    In a study of 312 patients with primary Sj&ouml;gren&rsquo;s, those with cardiovascular disease, compared with those without, were older; were less likely to have antinuclear antibodies, rheumatoid factor, or cryoglobulins; were more likely to have diabetes and dyslipidemia; and were more likely to have received glucocorticoids. However, the frequency of cardiovascular disease in the primary SS patients was no different than in matched controls without autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia is common in SS. This is most often due to lack of saliva, but there have also been reports of esophageal dysmotility similar to that seen in scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea, epigastric pain, and dyspepsia are other frequent complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/52\">",
"     52",
"    </a>",
"    ]. Histologic examination may show an atrophic gastritis with an infiltrate of predominantly CD4-positive T cells. Achlorhydria and pernicious anemia can also occur. A substantial percentage of patients with SS have antiparietal cell antibodies. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Serologic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who have gastritis should be examined for Helicobacter pylori, an organism associated with MALT lymphoma in SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Celiac disease (gluten enteropathy) may be more prevalent in patients with SS than in the general population. In a study of 111 patients with SS, histologically confirmed celiac disease was present in 5 patients, a rate that is approximately 10-fold higher than that in the general European population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported prevalence of celiac disease in SS is similar to that of celiac disease in such disorders as type 1 diabetes and autoimmune thyroid disease. In those disorders, noninvasive screening through autoantibody testing is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a clear association between SS and hepatic abnormalities as evidenced by abnormal biochemical tests or by biopsy features of primary biliary cirrhosis (PBC), portal tract fibrosis, or chronic active hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/55\">",
"     55",
"    </a>",
"    ]. Idiopathic portal hypertension has been associated with systemic sclerosis (scleroderma) and SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PBC have an increased prevalence of sicca symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/57\">",
"     57",
"    </a>",
"    ]. The explanation for this association is not clear, and there are other causes of abnormal liver function in SS, particularly hepatitis C virus infection and drug toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial nephritis, renal tubular dysfunction leading to renal tubular acidosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to decreased concentrating ability, and glomerular disease can occur in SS. Renal involvement is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=see_link\">",
"     \"Renal disease in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with SS may develop dysuria, urinary frequency, nocturia, and urgency. In the absence of a urinary tract infection, these symptoms in a patient with SS may be secondary to interstitial cystitis. The frequency of this symptom complex was evaluated in a study of 870 Finnish women with SS and of 1304 population controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/58\">",
"     58",
"    </a>",
"    ]. The presence of such urinary symptoms was 20-fold higher in those with SS (4 versus 0.2 percent in controls). The frequency of interstitial cystitis symptoms in RA patients with secondary SS was higher than in patients with RA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pancreas",
"    </span>",
"    &nbsp;&mdash;&nbsp;SS has been reported in association with autoimmune sclerosing pancreatitis, a disorder associated with diffuse or localized swelling of the pancreas and narrowing of the pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/60\">",
"     60",
"    </a>",
"    ]. Some patients thought to have SS and autoimmune pancreatitis may instead have IgG4-related systemic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H3#H3\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Mikulicz syndrome and IgG4-related disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Peripheral nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;SS is associated with a complex array of peripheral nervous system abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Peripheral neuropathy is estimated to occur in approximately 10 percent of patients with SS. With both peripheral and central nervous system involvement, neuropathic symptoms frequently precede the diagnosis of SS (81 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61,63\">",
"     61,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31879?source=see_link\">",
"     \"Approach to the patient with sensory loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overlap may occur among the different forms of peripheral neuropathy in SS. In a series of 92 patients, the following types of peripheral nervous system dysfunction were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory ataxia &mdash; Sensory ataxia occurred in 39 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"       61",
"      </a>",
"      ]. It is characterized by the impairment of deep sensory nerves without substantial motor symptoms. The initial symptom is usually paresthesias in the digits of the foot or hand, often beginning unilaterally and then spreading to the limbs, trunk, and face.",
"      <br/>",
"      <br/>",
"      Generalized areflexia is typically associated with sensory ataxia. Patients with advanced disease may become wheelchair-bound.",
"     </li>",
"     <li>",
"      Painful sensory neuropathy &mdash; Painful sensory neuropathy occurred in 20 percent of patients and can be seen in SS without sensory ataxia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"       61",
"      </a>",
"      ]. The initial symptoms are painful dysesthesias in the most distal portions of the limbs, usually beginning unilaterally. In the majority of patients, the spread of dysesthesias is chronic, occurring over months to years.",
"      <br/>",
"      <br/>",
"      Painful sensory neuropathies in SS typically have no electrophysiologic findings unless there is a concomitant large fiber neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. Decreased density of epidermal nerve fibers in a skin biopsy is a feature of small fiber neuropathy of various causes, including SS and diabetes mellitus.",
"     </li>",
"     <li>",
"      Pure sensory trigeminal neuropathy &mdash; Pure sensory trigeminal neuropathy occurred in 17 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"       61",
"      </a>",
"      ]. The characteristic feature is numbness or paresthesia restricted to the trigeminal region. Trigeminal nerve dysfunction in SS is caused by damage to the gasserian ganglion. The ophthalmic division is usually spared, thereby preserving the corneal reflex.",
"     </li>",
"     <li>",
"      Mononeuritis multiplex &mdash; Mononeuritis multiplex (also called multiple mononeuropathy) occurred in 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"       61",
"      </a>",
"      ]. The initial symptom of mononeuritis multiplex is the acute onset of tingling or painful dysesthesia in the distal limbs. Subsequently, motor and sensory symptoms occur episodically and extend to multiple nerve distributions, primarily in the limbs. The sudden onset and mononeuritis multiplex pattern is suggestive of a vasculitic neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=see_link\">",
"       \"Diagnosis and treatment of vasculitic neuropathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Nerve biopsy may be required to confirm the diagnosis of vasculitic neuropathy unless vasculitis is confirmed by biopsy of other involved organs. Biopsy of affected nerves often shows axonal degeneration and a perivascular inflammatory infiltrate, suggesting an underlying vasculitic cause in many cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/66\">",
"       66",
"      </a>",
"      ]. However, lymphocytic neural infiltration without vasculitis has been noted in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=see_link\">",
"       \"Diagnosis and treatment of vasculitic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple cranial neuropathies &mdash; Multiple cranial neuropathies occurred in 5 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"       61",
"      </a>",
"      ]. The extent and degree of cranial nerve involvement varied from patient to patient, and as many as six cranial nerves were involved. The cranial nerves most commonly affected were VII (Bell palsy); VIII (resulting in neural deafness and vestibular dysfunction); and III, IV, or VI (resulting in diplopia).Hearing may also be affected in a significant proportion of patients, although many cases are subclinical [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/67\">",
"       67",
"      </a>",
"      ]. In a study of 30 SS patients, all subjects underwent systematic evaluations for hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/68\">",
"       68",
"      </a>",
"      ]. Fourteen (46 percent) had sensorineural hearing loss on audiometric testing, compared with only 2.5 percent of the controls. Five of the 14 SS patients had clinically apparent hearing loss.",
"     </li>",
"     <li>",
"      Radiculoneuropathy &mdash; Radiculoneuropathy occurred in 4 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"       61",
"      </a>",
"      ]. This disorder is characterized by sensorimotor dysfunction with both progressive sensory impairment and muscle weakness. The primary lesion in these patients appears to be in the spinal nerve roots or in the most proximal nerve trunks, consistent with an inflammatory radiculoneuropathy. The cerebrospinal fluid protein concentration is usually elevated, but pleocytosis is absent.",
"     </li>",
"     <li>",
"      Autonomic neuropathy &mdash; Autonomic neuropathy occurred in 3 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"       61",
"      </a>",
"      ]. Clinical features of autonomic neuropathy include severe orthostatic hypotension, hypohidrosis or anhidrosis of the trunk and limbs, abdominal pain, constipation, diarrhea, and Adie&rsquo;s pupils. Adie&rsquo;s pupils are characterized by tonic dilation resulting from damage to the postganglionic fibers of the parasympathetic innervation of the eye. The pupils react poorly to light but react slowly to accommodation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=see_link\">",
"       \"Diabetic autonomic neuropathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Autonomic dysfunction may contribute to the esophageal motility changes seen in SS and even to the decreased lacrimation and salivation of the sicca complex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25162?source=see_link\">",
"       \"Pathogenesis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of central nervous system involvement in SS (CNS-SS) is a matter of controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/69\">",
"     69",
"    </a>",
"    ]. In some patients, 20 to 25 percent of patients with primary SS had CNS manifestations, ranging from focal central lesions to dementia and conditions that mimic multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/70\">",
"     70",
"    </a>",
"    ]. However, other groups have found a much lower prevalence of CNS-SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/66,71,72\">",
"     66,71,72",
"    </a>",
"    ]. Furthermore, the relationship between cerebral white matter lesions reported in some magnetic resonance imaging (MRI) studies and clinical manifestations is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential explanations for the apparent discrepancy in prevalence of CNS-SS include referral bias, disagreement about diagnostic criteria, differences in the thoroughness with which CNS-SS is sought, and lack of a standard with which to interpret MRI findings.",
"   </p>",
"   <p>",
"    Any part of the brain or spinal cord can be affected. The pattern is generally one of multifocal recurrent episodes, often separated by long disease-free intervals, resulting in an insidious progressive neurologic deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Awareness of the possibility of CNS disease is important because of the potentially serious nature of CNS complications and because of the fact that some are treatable with immunosuppressive medications. On the hand, the neurologic symptoms often precede the onset of SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=see_link&amp;anchor=H26015999#H26015999\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The range of CNS findings includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal lesions may result in motor or sensory deficits, seizures, or cerebellar syndromes.",
"     </li>",
"     <li>",
"      Diffuse brain lesions can be manifested by encephalopathy or psychiatric abnormalities ranging from subtle cognitive impairments to frank dementia.",
"     </li>",
"     <li>",
"      Spinal cord involvement can lead to acute transverse myelopathy or to a progressive myelopathy. Neuromyelitis optica has been reported in a few cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subacute aseptic meningitis with diffuse leptomeningeal enhancement has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chorea has been described as a presenting symptom [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Optic neuritis may be the presenting symptom or a later complication in as many as 16 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/74,77\">",
"       74,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although infrequently mentioned by patients, subtle changes in cognitive function with poor memory and concentration may occur. These changes can be confirmed on formal cognitive testing [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/78,79\">",
"       78,79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Fatigue and fibromyalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is one of the most common complaints in SS, but its pathogenesis remains incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/80\">",
"     80",
"    </a>",
"    ]. Patients with SS suffer from sleep disorders usually due to disruption of sleep patterns by a cycle of xerostomia-stimulating polydipsia and, therefore, polyuria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/81\">",
"     81",
"    </a>",
"    ]. Fibromyalgia, usually accompanied by fatigue, is also very common in SS. In some SS patients, fatigue is due to hypothyroidism or to chronic inflammation, probably mediated by cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric conditions, including depression and personality disorders, appear to be common in SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/72,79\">",
"     72,79",
"    </a>",
"    ]. The pathophysiologic basis of these disturbances in SS is unclear. In the past, it has been attributed, probably erroneously in most cases, to vasculitis. In some cases of SS, psychiatric findings may represent a response to the stress of chronic illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major long-term concern for patients with SS is the development of lymphoma. SS is characterized by polyclonal B-cell activation as well as by lymphocytic infiltration of the exocrine glands. In ways that remain unclear, the B-cell activation in SS predisposes some patients to the development of lymphoma. Most lymphomas arise from a reactive infiltrate called lymphoepithelial sialadenitis or benign lymphoepithelial lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lifetime risk of non-Hodgkin lymphoma (NHL) is approximately 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11,22,83,84\">",
"     11,22,83,84",
"    </a>",
"    ], which is 16 to 44 times higher than that of the normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Thus, in most patients, lymphoproliferation remains confined to the glandular tissue and does not undergo malignant transformation.",
"   </p>",
"   <p>",
"    Monoclonal B-cell proliferation precedes the clinical onset of lymphoma in SS. In a series of 237 patients, a monoclonal spike was found in the serum of 16 and 46 percent of patients with primary and hepatitis C-associated SS, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The transition from SS to lymphoma is a process that requires many years. In two series, the diagnosis of lymphoma occurred at a mean of 6.5 to 7.5 years after the diagnosis of SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/22,84\">",
"     22,84",
"    </a>",
"    ]. The factors that are involved in this transition are not well-understood.",
"   </p>",
"   <p>",
"    If the cells are pleomorphic but fail to meet criteria for true malignancy, the term &ldquo;pseudolymphoma&rdquo; is applied (",
"    <a class=\"graphic graphic_picture graphicRef76275 \" href=\"UTD.htm?14/38/14946\">",
"     picture 3",
"    </a>",
"    ). This may present as lymphadenopathy or as functional impairment of an affected organ, such as kidney or lung, but does not necessarily proceed to full-blown lymphoma. The distinction between pseudolymphoma and lymphoma is often difficult, although the former should have no evidence for B-cell or T-cell clonality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Genetic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of clinical features appears to identify patients with SS who are at increased risk for lymphoma development. Among the patients in this registry, the following extraglandular manifestations were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cutaneous vasculitis &mdash; 60 percent",
"     </li>",
"     <li>",
"      Peripheral neuropathy &mdash; 48 percent",
"     </li>",
"     <li>",
"      Rheumatoid factor positivity &mdash; 96 percent",
"     </li>",
"     <li>",
"      Type II cryoglobulins &mdash; 80 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors identified in other studies include",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibody positivity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/65\">",
"     65",
"    </a>",
"    ] and infiltration of salivary glandular tissue by dendritic cells and macrophages that express the cytokines interleukin (IL)-12 and IL-18 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been considerable speculation about the role of infectious agents in the transition to lymphoma. Hepatitis C virus (HCV) is particularly intriguing in this regard because of its known sialotropic and oncogenic potential. In an international registry of 25 patients with SS, HCV infection, and lymphoma, the following types of B-cell lymphoma were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphoma involving mucosa associated lymphoid tissue (MALT) occurred in 11 patients (44 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Extranodal (MALT) MZL'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffuse large B-cell lymphoma occurred in 6 patients (24 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Follicular center cell lymphoma occurred in 6 patients (24 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy outcomes among patients with SS are generally similar to those of healthy women. However, women with SS who have",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    antibodies are at risk for giving birth to babies with neonatal lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Among the manifestations of neonatal lupus, the greatest concern is congenital heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. The risk of congenital heart block among the offspring of pregnant SS women who are",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    antibody positive is approximately 4 percent. Other features of neonatal lupus include cutaneous manifestations, transient hepatitis, thrombocytopenia, and anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heart block can also occur in adult SS patients and may be associated with antibodies against Purkinje fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/93\">",
"     93",
"    </a>",
"    ], muscarinic M1 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/94\">",
"     94",
"    </a>",
"    ], and",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/95\">",
"     95",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life is impaired by SS. This was illustrated in a study that used the short-form 36 (SF-36) to compare patients with primary SS with a control population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/96\">",
"     96",
"    </a>",
"    ]. The SS patients showed significantly lower scores than controls in all SF-36 domains. Patients with extraglandular involvement had lower scores for vitality, social functioning, bodily pain, and general health compared with patients without extraglandular features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing lymphoma is increased in patients with SS, particularly in those with primary disease. The largest series of 380 Spanish patients with primary SS found that 3 percent had developed lymphoma during nine years of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"     11",
"    </a>",
"    ]. This prevalence is similar to that from a summary of published reports that included 2311 patients (4 percent during follow-up periods of 2 to 27 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with SS and with severe involvement of the exocrine glands, vasculitis, and cryoglobulinemia are at increased risk for developing lymphoma and, thus, should be monitored for this (rare) complication [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the association between SS and lymphoproliferative disorders, there is contradictory evidence regarding overall survival of patients with this disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study, 723 patients with primary SS were followed for a mean of six years, with mortality rates that were compared with a gender- and age-matched segment of the same population [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/98\">",
"       98",
"      </a>",
"      ]; the small increase in the standardized mortality ratio (SMR) for those with primary SS was not statistically significantly (SMR 1.15, 95% CI 0.86-1.73).",
"     </li>",
"     <li>",
"      A modestly but statistically significantly higher SMR was found in a study of 4979 Scottish patients with SS who were followed for a mean of seven years (SMR for men was 1.71, 95% CI 1.21-2.35, and for women was 2.01, 95% CI 1.76-2.30) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypocomplementemia appears to be an independent risk factor for premature death. In one study cited above, among a variety of clinical and laboratory variables examined, only a depressed serum C4 complement level remained a significant risk factor for a shortened life span after multivariate analysis (hazard ratio 4.39, 95% CI 2.18-8.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/98\">",
"     98",
"    </a>",
"    ]. The association between poor prognosis and depressed complement level has been independently confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/42/27306/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with SS may have involvement of many types of organs beyond the exocrine glands. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Extraglandular organ involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain serologic findings correlate highly with specific clinical features in SS. Common serologic findings include antinuclear antibodies,",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies, rheumatoid factor, cryoglobulinemia, and hypocomplementemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous vasculitis in SS may be either a leukocytoclastic vasculitis or a lymphocytic vasculitis. Cutaneous vasculitis is often associated with antibodies to the",
"      <span class=\"nowrap\">",
"       Ro/SSA",
"      </span>",
"      antigen, cryoglobulins, and hypocomplementemia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cutaneous vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SS may be associated with skin disease that is identical to the skin lesions of subacute cutaneous lupus erythematosus. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Annular erythema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interstitial lung disease can occur in SS in the form of lymphocytic interstitial pneumonitis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Lungs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SS can cause a complex array of peripheral nervous system and brain abnormalities. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Peripheral nervous system'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lifetime risk of non-Hodgkin lymphoma (NHL) in primary SS is approximately 5 percent. NHL occurs at a mean of approximately seven years after the diagnosis of SS. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of congenital heart block among the offspring of pregnant SS women who are",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibody positive is approximately 3 to 4 percent. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/1\">",
"      Ramos-Casals M, Tzioufas AG, Font J. Primary Sj&ouml;gren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/2\">",
"      Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis 1999; 58:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/3\">",
"      Asmussen K, Andersen V, Bendixen G, et al. A new model for classification of disease manifestations in primary Sj&ouml;gren's syndrome: evaluation in a retrospective long-term study. J Intern Med 1996; 239:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/4\">",
"      Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sj&ouml;gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/5\">",
"      Vitali C. Classification criteria for Sj&ouml;gren's syndrome. Ann Rheum Dis 2003; 62:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/6\">",
"      Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sj&ouml;gren's syndrome: a data-driven, expert consensus approach in the Sj&ouml;gren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/7\">",
"      Malladi AS, Sack KE, Shiboski SC, et al. Primary Sj&ouml;gren's syndrome as a systemic disease: a study of participants enrolled in an international Sj&ouml;gren's syndrome registry. Arthritis Care Res (Hoboken) 2012; 64:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/8\">",
"      Garc&iacute;a-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sj&ouml;gren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002; 81:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/9\">",
"      Haneji N, Nakamura T, Takio K, et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sj&ouml;gren's syndrome. Science 1997; 276:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/10\">",
"      Willeke P, Gaubitz M, Schotte H, et al. Clinical and immunological characteristics of patients with Sj&ouml;gren's syndrome in relation to alpha-fodrin antibodies. Rheumatology (Oxford) 2007; 46:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/11\">",
"      Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sj&ouml;gren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) 2002; 81:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/12\">",
"      BLOCH KJ, BUCHANAN WW, WOHL MJ, BUNIM JJ. SJOEGREN'S SYNDROME. A CLINICAL, PATHOLOGICAL, AND SEROLOGICAL STUDY OF SIXTY-TWO CASES. Medicine (Baltimore) 1965; 44:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/13\">",
"      Martinez-Lavin M, Vaughan JH, Tan EM. Autoantibodies and the spectrum of Sj&ouml;gren's syndrome. Ann Intern Med 1979; 91:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/14\">",
"      Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sj&ouml;gren's syndrome. Arthritis Rheum 1996; 39:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/15\">",
"      Roguedas AM, Misery L, Sassolas B, et al. Cutaneous manifestations of primary Sj&ouml;gren's syndrome are underestimated. Clin Exp Rheumatol 2004; 22:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/16\">",
"      Fox RI, Liu AY. Sj&ouml;gren's syndrome in dermatology. Clin Dermatol 2006; 24:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/17\">",
"      Provost TT, Watson R. Cutaneous manifestations of Sj&ouml;gren's syndrome. Rheum Dis Clin North Am 1992; 18:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/18\">",
"      Bernacchi E, Amato L, Parodi A, et al. Sj&ouml;gren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 2004; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/19\">",
"      Bernacchi E, Bianchi B, Amato L, et al. Xerosis in primary Sj&ouml;gren syndrome: immunohistochemical and functional investigations. J Dermatol Sci 2005; 39:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/20\">",
"      Ellman P, Weber FP, Goodier TE. Contribution to pathology of Sj&ouml;gren's syndrome. Q J Med 1951; 20:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/21\">",
"      Ramos-Casals M, Anaya JM, Garc&iacute;a-Carrasco M, et al. Cutaneous vasculitis in primary Sj&ouml;gren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004; 83:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/22\">",
"      Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sj&ouml;gren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sj&ouml;gren's Syndrome. Arthritis Rheum 1999; 42:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/23\">",
"      Ferreiro JE, Pasarin G, Quesada R, Gould E. Benign hypergammaglobulinemic purpura of Waldenstr&ouml;m associated with Sj&ouml;gren's syndrome. Case report and review of immunologic aspects. Am J Med 1986; 81:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/24\">",
"      Alexander EL, Arnett FC, Provost TT, Stevens MB. Sj&ouml;gren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 1983; 98:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/25\">",
"      Kraus A, Caballero-Uribe C, Jakez J, et al. Raynaud's phenomenon in primary Sj&ouml;gren's syndrome. Association with other extraglandular manifestations. J Rheumatol 1992; 19:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/26\">",
"      Garc&iacute;a-Carrasco M, Sis&oacute; A, Ramos-Casals M, et al. Raynaud's phenomenon in primary Sj&ouml;gren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002; 29:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/27\">",
"      Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/28\">",
"      Yoneyama K, Tochigi N, Oikawa A, et al. Primary localized cutaneous nodular amyloidosis in a patient with Sj&ouml;gren's syndrome: a review of the literature. J Dermatol 2005; 32:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/29\">",
"      Pease CT, Shattles W, Barrett NK, Maini RN. The arthropathy of Sj&ouml;gren's syndrome. Br J Rheumatol 1993; 32:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/30\">",
"      Kamali S, Polat NG, Kasapoglu E, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sj&ouml;gren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005; 24:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/31\">",
"      Lindvall B, Bengtsson A, Ernerudh J, Eriksson P. Subclinical myositis is common in primary Sj&ouml;gren's syndrome and is not related to muscle pain. J Rheumatol 2002; 29:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/32\">",
"      Foster H, Fay A, Kelly C, et al. Thyroid disease and other autoimmune phenomena in a family study of primary Sj&ouml;gren's syndrome. Br J Rheumatol 1993; 32:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/33\">",
"      P&eacute;rez B, Kraus A, L&oacute;pez G, et al. Autoimmune thyroid disease in primary Sj&ouml;gren's syndrome. Am J Med 1995; 99:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/34\">",
"      D'Arbonneau F, Ansart S, Le Berre R, et al. Thyroid dysfunction in primary Sj&ouml;gren's syndrome: a long-term followup study. Arthritis Rheum 2003; 49:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/35\">",
"      Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in families with primary Sj&ouml;gren's syndrome. J Rheumatol 2006; 33:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/36\">",
"      Ramos-Casals M, Garc&iacute;a-Carrasco M, Cervera R, et al. Thyroid disease in primary Sj&ouml;gren syndrome. Study in a series of 160 patients. Medicine (Baltimore) 2000; 79:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/37\">",
"      Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/38\">",
"      Dalvi V, Gonzalez EB, Lovett L. Lymphocytic interstitial pneumonitis (LIP) in Sj&ouml;gren's syndrome: a case report and a review of the literature. Clin Rheumatol 2007; 26:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/39\">",
"      Kurumagawa T, Kobayashi H, Motoyoshi K. Potential involvement of subclinical Sj&ouml;gren's syndrome in various lung diseases. Respirology 2005; 10:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/40\">",
"      Matsuyama N, Ashizawa K, Okimoto T, et al. Pulmonary lesions associated with Sj&ouml;gren's syndrome: radiographic and CT findings. Br J Radiol 2003; 76:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/41\">",
"      Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004; 10:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/42\">",
"      Xu B, Wagner N, Pham LN, et al. Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways. J Exp Med 2003; 197:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/43\">",
"      Berman JS, Beer DJ, Theodore AC, et al. Lymphocyte recruitment to the lung. Am Rev Respir Dis 1990; 142:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/44\">",
"      Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/45\">",
"      Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. N Engl J Med 2006; 355:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/46\">",
"      Gy&ouml;ngy&ouml;si M, Pokorny G, Jambrik Z, et al. Cardiac manifestations in primary Sj&ouml;gren's syndrome. Ann Rheum Dis 1996; 55:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/47\">",
"      Mohri H, Kimura M, Ieki R, et al. Cardiac tamponade in Sj&ouml;gren's syndrome. J Rheumatol 1986; 13:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/48\">",
"      Rantap&auml;&auml;-Dahlqvist S, Backman C, Sandgren H, Ostberg Y. Echocardiographic findings in patients with primary Sj&ouml;gren's syndrome. Clin Rheumatol 1993; 12:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/49\">",
"      P&eacute;rez-De-Lis M, Akasbi M, Sis&oacute; A, et al. Cardiovascular risk factors in primary Sj&ouml;gren's syndrome: a case-control study in 624 patients. Lupus 2010; 19:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/50\">",
"      Ramirez-Mata M, Pena Ancira FF, Alarcon-Segovia D. Abnormal esophageal motility in primary Sj&ouml;gren's syndrome. J Rheumatol 1976; 3:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/51\">",
"      Palma R, Freire A, Freitas J, et al. Esophageal motility disorders in patients with Sj&ouml;gren's syndrome. Dig Dis Sci 1994; 39:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/52\">",
"      Maury CP, T&ouml;rnroth T, Teppo AM. Atrophic gastritis in Sj&ouml;gren's syndrome. Morphologic, biochemical, and immunologic findings. Arthritis Rheum 1985; 28:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/53\">",
"      Raderer M, Osterreicher C, Machold K, et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol 2001; 12:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/54\">",
"      Szodoray P, Barta Z, Lakos G, et al. Coeliac disease in Sj&ouml;gren's syndrome--a study of 111 Hungarian patients. Rheumatol Int 2004; 24:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/55\">",
"      Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sj&ouml;gren's syndrome. Br J Rheumatol 1994; 33:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/56\">",
"      Kogawa H, Migita K, Ito M, et al. Idiopathic portal hypertension associated with systemic sclerosis and Sj&ouml;gren's syndrome. Clin Rheumatol 2005; 24:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/57\">",
"      Tsianos EV, Hoofnagle JH, Fox PC, et al. Sj&ouml;gren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990; 11:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/58\">",
"      Leppilahti M, Tammela TL, Huhtala H, et al. Interstitial cystitis-like urinary symptoms among patients with Sj&ouml;gren's syndrome: a population-based study in Finland. Am J Med 2003; 115:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/59\">",
"      Lee KL, Chen MY, Yeh JH, et al. Lower urinary tract symptoms in female patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/60\">",
"      Matsuda M, Hamano H, Yoshida T, et al. Seronegative Sj&ouml;gren syndrome with asymptomatic autoimmune sclerosing pancreatitis. Clin Rheumatol 2007; 26:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/61\">",
"      Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sj&ouml;gren's syndrome-associated neuropathy. Brain 2005; 128:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/62\">",
"      Dyck PJ. The clinical heterogeneity of immune sensory and autonomic neuropathies with (or without) sicca. Brain 2005; 128:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/63\">",
"      Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sj&ouml;gren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/64\">",
"      Chai J, Herrmann DN, Stanton M, et al. Painful small-fiber neuropathy in Sjogren syndrome. Neurology 2005; 65:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/65\">",
"      Font J, Ramos-Casals M, de la Red G, et al. Pure sensory neuropathy in primary Sj&ouml;gren's syndrome. Longterm prospective followup and review of the literature. J Rheumatol 2003; 30:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/66\">",
"      Mellgren SI, Conn DL, Stevens JC, Dyck PJ. Peripheral neuropathy in primary Sj&ouml;gren's syndrome. Neurology 1989; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/67\">",
"      Freeman SR, Sheehan PZ, Thorpe MA, Rutka JA. Ear, nose, and throat manifestations of Sj&ouml;gren's syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol 2005; 34:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/68\">",
"      Tumiati B, Casoli P, Parmeggiani A. Hearing loss in the Sj&ouml;gren syndrome. Ann Intern Med 1997; 126:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/69\">",
"      Moutsopoulos HM, Sarmas JH, Talal N. Is central nervous system involvement a systemic manifestation of primary Sj&ouml;gren's syndrome? Rheum Dis Clin North Am 1993; 19:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/70\">",
"      Alexander EL. Neurologic disease in Sj&ouml;gren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993; 19:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/71\">",
"      Binder A, Snaith ML, Isenberg D. Sj&ouml;gren's syndrome: a study of its neurological complications. Br J Rheumatol 1988; 27:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/72\">",
"      Hietaharju A, Yli-Kerttula U, H&auml;kkinen V, Frey H. Nervous system manifestations in Sj&ouml;gren's syndrome. Acta Neurol Scand 1990; 81:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/73\">",
"      Coates T, Slavotinek JP, Rischmueller M, et al. Cerebral white matter lesions in primary Sj&ouml;gren's syndrome: a controlled study. J Rheumatol 1999; 26:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/74\">",
"      Rabadi MH, Kundi S, Brett D, Padmanabhan R. Neurological pictures. Primary Sj&ouml;gren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/75\">",
"      Rossi R, Valeria Saddi M. Subacute aseptic meningitis as neurological manifestation of primary Sj&ouml;gren's syndrome. Clin Neurol Neurosurg 2006; 108:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/76\">",
"      Venegas Fanchke P, Sinning M, Miranda M. Primary Sjogren's syndrome presenting as a generalized chorea. Parkinsonism Relat Disord 2005; 11:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/77\">",
"      Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/78\">",
"      Malinow KL, Molina R, Gordon B, et al. Neuropsychiatric dysfunction in primary Sj&ouml;gren's syndrome. Ann Intern Med 1985; 103:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/79\">",
"      Valt&yacute;sd&oacute;ttir ST, Gudbj&ouml;rnsson B, Lindqvist U, et al. Anxiety and depression in patients with primary Sj&ouml;gren's syndrome. J Rheumatol 2000; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/80\">",
"      Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary Sj&ouml;gren's syndrome. Ann Rheum Dis 1998; 57:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/81\">",
"      Gudbj&ouml;rnsson B, Broman JE, Hetta J, H&auml;llgren R. Sleep disturbances in patients with primary Sj&ouml;gren's syndrome. Br J Rheumatol 1993; 32:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/82\">",
"      Tapinos NI, Polihronis M, Moutsopoulos HM. Lymphoma development in Sj&ouml;gren's syndrome: novel p53 mutations. Arthritis Rheum 1999; 42:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/83\">",
"      Janin A, Morel P, Quiquandon I, et al. Non-Hodgkin's lymphoma and Sj&ouml;gren's syndrome. An immunopathological study of 113 patients. Clin Exp Rheumatol 1992; 10:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/84\">",
"      Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sj&ouml;gren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol 1995; 24:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/85\">",
"      Lazarus MN, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2006; 45:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/86\">",
"      Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sj&ouml;gren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/87\">",
"      Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/88\">",
"      Brito-Zer&oacute;n P, Ramos-Casals M, Nardi N, et al. Circulating monoclonal immunoglobulins in Sj&ouml;gren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore) 2005; 84:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/89\">",
"      Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sj&ouml;gren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007; 57:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/90\">",
"      Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sj&ouml;gren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007; 56:3977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/91\">",
"      Haga HJ, Gjesdal CG, Koksvik HS, et al. Pregnancy outcome in patients with primary Sj&ouml;gren's syndrome. a case-control study. J Rheumatol 2005; 32:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/92\">",
"      Steele JC, Dawson LJ, Moots RJ, Field EA. Congenital heart block associated with undiagnosed maternal Primary Sj&ouml;gren's Syndrome -- a case report and discussion. Oral Dis 2005; 11:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/93\">",
"      Obbiassi M, Brucato A, Meroni PL, et al. Antibodies to cardiac Purkinje cells: further characterization in autoimmune diseases and atrioventricular heart block. Clin Immunol Immunopathol 1987; 42:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/94\">",
"      Borda E, Sterin-Borda L. Autoantibodies against neonatal heart M1 muscarinic acetylcholine receptor in children with congenital heart block. J Autoimmun 2001; 16:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/95\">",
"      Lodde BM, Sankar V, Kok MR, et al. Adult heart block is associated with disease activity in primary Sj&ouml;gren's syndrome. Scand J Rheumatol 2005; 34:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/96\">",
"      Belenguer R, Ramos-Casals M, Brito-Zer&oacute;n P, et al. Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sj&ouml;gren's syndrome. Clin Exp Rheumatol 2005; 23:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/97\">",
"      Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sj&ouml;gren's syndrome. Clin Exp Rheumatol 2008; 26:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/98\">",
"      Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj&ouml;gren's syndrome. Arthritis Rheum 2002; 46:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/99\">",
"      Thomas E, Symmons DP, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003; 30:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/42/27306/abstract/100\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Yag&uuml;e J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2005; 44:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5593 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27306=[""].join("\n");
var outline_f26_42_27306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTRAGLANDULAR ORGAN INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anti-Ro/SSA and anti-La/SSB antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Anti-alpha-fodrin antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cryoglobulins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypergammaglobulinemia and hypogammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Monoclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Xerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cutaneous vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Annular erythema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Joints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lungs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Kidneys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pancreas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Peripheral nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Fatigue and fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5593|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/20/43333\" title=\"picture 1A\">",
"      Leukocytoclastic vasculitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/37/23126\" title=\"picture 1B\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/32/13825\" title=\"picture 2\">",
"      Subacute cutaneous lupus I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/38/14946\" title=\"picture 3\">",
"      Pseudolymphoma in Sjogrens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31879?source=related_link\">",
"      Approach to the patient with sensory loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=related_link\">",
"      Diabetic autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=related_link\">",
"      Diagnosis and treatment of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=related_link\">",
"      Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=related_link\">",
"      Lymphoid interstitial pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25162?source=related_link\">",
"      Pathogenesis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=related_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34633?source=related_link\">",
"      Respiratory bronchiolitis-associated interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=related_link\">",
"      Treatment of dry eyes in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=related_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_42_27307="Physiologic Rx Malnutrition C";
var content_f26_42_27307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic basis for treatment of severe malnutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Affected organ or system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cellular function",
"       </td>",
"       <td>",
"        Sodium pump activity is reduced and cell membranes are more",
"permeable than normal, which leads to an increase in intracellular",
"sodium and a decrease in intracellular potassium and magnesium",
"        <br/>",
"        Protein synthesis is reduced",
"       </td>",
"       <td>",
"        Give large doses of potassium and magnesium to all children",
"        <br/>",
"        Restrict sodium intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin, muscles and glands",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        The skin and subcutaneous fat are atrophied, which leads to loose folds of skin",
"        <br/>",
"        Many signs of dehydration are unreliable; eyes may be sunken because of loss of subcutaneous fat in the orbit",
"        <br/>",
"        Many glands, including the sweat, tear and salivary glands,",
"are atrophied; the child has dryness of the mouth and eyes and sweat",
"production is reduced",
"        <br/>",
"        Respiratory muscles are easily fatigued; the child is lacking in energy",
"       </td>",
"       <td>",
"        Rehydrate the child with ReSoMal or F-75 diet",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27307=[""].join("\n");
var outline_f26_42_27307=null;
var title_f26_42_27308="ADHD resources";
var content_f26_42_27308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for families of children with attention deficit hyperactivity disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CHADD is a national advocacy organization for individuals affected by AD/HD and organizes local chapters for information and support.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.chadd.org/\" target=\"_blank\">",
"         www.chadd.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Alliance for the Mentally Ill (NAMI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NAMI is a national advocacy organization for individuals affected by mental illness. NAMI provides general information and support opportunities for many mental illnesses.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.nami.org/\" target=\"_blank\">",
"         www.nami.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Attention Deficit Disorder Association (ADDA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADDA is a non-profit, national organization that advocates for the needs of ADHD individuals and their families. ADDA is a resource for a variety of information and current research and policy updates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.add.org/\" target=\"_blank\">",
"         www.add.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Institute of Mental Health (NIMH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The NIMH provides a number of booklets about ADHD that can be downloaded free of charge.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.nimh.nih.gov/health/publications/adhd-listing.shtml\" target=\"_blank\">",
"         www.nimh.nih.gov/health/publications/adhd-listing.shtml",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The United States Department of Education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The United States Department of Education, Office of Special Education Programs provides information on educational policy and research related to ADHD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www2.ed.gov/about/offices/list/osers/index.html\" target=\"_blank\">",
"         www2.ed.gov/about/offices/list/osers/index.html",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The American Academy of Child and Adolescent Psychiatry (AACAP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The American Academy of Child and Adolescent Psychiatry provides fact sheets about AD/HD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.aacap.org/cs/root/facts_for_families/children_who_cant_pay_attention/attention_deficit_hyperactivity_disorder\" target=\"_blank\">",
"         www.aacap.org/cs/root/facts_for_families/children_who_cant_pay_attention/attention_deficit_hyperactivity_disorder",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27308=[""].join("\n");
var outline_f26_42_27308=null;
var title_f26_42_27309="Dobut response outcome CABG";
var content_f26_42_27309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Response to dobutamine predicts regional ventricular function recovery after bypass surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 211px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left ventricular segments that show a biphasic response with a dobutamine echocardiogram (improvement with low dose dobutamine followed by deterioration at higher doses) have the best functional improvement three months after surgery. Segments that show improvement only, worsen, or do not change have little likelihood of recovery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cornel JH, Bax JJ, Elhendy A, et al. J Am Coll Cardiol 1998; 31:1002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27309=[""].join("\n");
var outline_f26_42_27309=null;
var title_f26_42_27310="Contents: Scleroderma";
var content_f26_42_27310=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Scleroderma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Scleroderma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Classification and diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44087\">",
"           Classification of scleroderma disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43095\">",
"           Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/10/8360\">",
"           Eosinophilic fasciitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29224\">",
"           Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eosinophilic fasciitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/10/8360\">",
"           Eosinophilic fasciitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/35/41529\">",
"           Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11415\">",
"           Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lung disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/45/26329\">",
"           Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/19/7482\">",
"           Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6935\">",
"           Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous manifestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/48/778\">",
"           Neuromuscular manifestations of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Overlap syndromes and undifferentiated disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/24/43401\">",
"           Clinical manifestations of mixed connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/23/3447\">",
"           Definition and diagnosis of mixed connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19095\">",
"           Prognosis and treatment of mixed connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42968\">",
"           Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/65\">",
"           Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34244\">",
"           Systemic sclerosis (scleroderma) and pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Raynaud phenomenon",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/48/6921\">",
"           Clinical manifestations and diagnosis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/34/28200\">",
"           Initial treatment of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/30/28138\">",
"           Treatment of the Raynaud phenomenon resistant to initial therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/61/35801\">",
"           Scleroderma renal crisis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16008\">",
"           General principles of the use of cyclophosphamide in rheumatic and renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/18/23849\">",
"           Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/20/13642\">",
"           Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/11/37045\">",
"           Pretreatment evaluation of adults with systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/19/7482\">",
"           Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6935\">",
"           Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/46/9958\">",
"           Surgery in patients with systemic sclerosis (scleroderma) of the hand",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-7851F96B36-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_42_27310=[""].join("\n");
var outline_f26_42_27310=null;
var title_f26_42_27311="Early acromegalic arthropathy";
var content_f26_42_27311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain film of the hand in a 53-year-old woman who presented with enlarged hands shows thickening of the soft tissues, exaggeration of the bony tufts of the distal phalanges, and prominence of the muscular attachments of the proximal phalanges. These are all features consistent with acromegaly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_42_27311=[""].join("\n");
var outline_f26_42_27311=null;
